

CV updated: 1 January 2024

Personal Data

Name: Jerome Amir Singh
Birthplace: Durban, South Africa
Citizenship: South African

Tertiary education

Degrees

Year awarded	Degree	Institution	Degree field
1995	Bachelor of Arts (BA)	University of Natal	Psychology and Law
1997	Bachelor of Law (LLB)	University of Natal	Law
1998	Master of Law (LLM)	University of Natal	Law (<i>cum laude</i>)
2002	Doctor of Philosophy (PhD)	University of Natal	Law
2003	Master of Health Sciences (MHSc)	University of Toronto	Bioethics (A+ average)

Non-degree education and training

July 1999	Genetics and Ethics (Professional development course), University of Colorado, Aspen, USA.
Sept 1999	Medical Ethics (Professional development course), Imperial College, University of London, London, UK.
April 2000	Public Health Ethics (MPH course credit), University of Adelaide, Adelaide, Australia.
June 2001	Ethical Issues in International Health Research (Professional Development course), Harvard University, Boston, USA.
Aug 2002-June 2003	Fogarty International Centre post-doctoral fellowship in Bioethics, University of Toronto Joint Center for Bioethics, Toronto, Canada.
Feb 2003-May 2003	Internship at the AIDS Committee of Toronto (ACT), Toronto, Canada.
June 2004	Health and Human Rights (Professional development course), Harvard University, Boston, USA.

Appointments

South Africa

Past

1995-1996	<u>Tutor</u> : Howard College School of Law, University of Natal, Durban.
1997-1998	<u>Lecturer</u> : Howard College School of Law, University of Natal, Durban.
1999-2004	<u>Senior Lecturer</u> : Howard College School of Law, University of KwaZulu-Natal, Durban.
1999-2000	<u>External Examiner</u> : <i>Commercial Law 220</i> , School of Law, University of Natal, Pietermaritzburg.
2000-2001	<u>External Examiner</u> : <i>Institutional Framework</i> , Masters of Public Health Law program, Faculty of Law, University of Durban-Westville.
2001	<u>External Examiner</u> : <i>Emerging Public Health Issues in Developing Countries</i> , Master of Public Health Law program, University of Durban-Westville.
2001-2002	<u>External Examiner</u> : <i>Telecommunications Law</i> , LLB programme, University of Witwatersrand, Johannesburg.
2001-2002	<u>External Examiner</u> : <i>Public health, Human Rights, and Ethics</i> , Master of Public Health Law program, University of Durban-Westville.

2001-2004	<u>External Examiner:</u> <i>Health and Human Rights</i> , Master of Public Health Law program, University of Durban-Westville (renamed UKZN, Westville since Jan 2004).
2002-2004	<u>External Examiner:</u> <i>Ethics and Human Rights</i> , Master of Public Health Law program, University of Durban-Westville (renamed UKZN, Westville since Jan 2004).
2005-2008	<u>Honorary Research Fellow:</u> Howard College School of Law, University of KwaZulu-Natal, Durban.
1999-2012	<u>Course Director:</u> Bioethics (undergraduate course), Howard College School of Law, University of KwaZulu-Natal, Durban.
2007-2008	<u>External Examiner:</u> <i>Public Health and Human Rights</i> , University of Cape Town.
2007-2014	<u>External Examiner:</u> <i>Bioethics</i> , School of Law, Pietermaritzburg, University of KwaZulu-Natal, Pietermaritzburg.
2008-2014	<u>External Examiner:</u> <i>Legal Medicine; Forensic Medicine</i> , University of Stellenbosch.
2003-2020	<u>Head:</u> Ethics and Health Law, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.

Current

<u>2000-current</u>	<u>Course Director:</u> Bioethics and the Law (post-graduate course), Howard College School of Law, University of KwaZulu-Natal, Durban.
<u>2020-current</u>	<u>Honorary Research Fellow:</u> Howard College School of Law, University of KwaZulu-Natal, Durban, South Africa.
<u>2016-current</u>	<u>Director:</u> Ethical Legal, Social Issues (ELSI) Advisory Services on Global Health Research and Development (Durban, South Africa and Toronto, Canada).
<u>2020-current</u>	<u>Member:</u> Bioethics Advisory Panel, South African Medical Research Council.
<u>2021-current</u>	<u>Principal Investigator/Director:</u> Scientific Advisory Group on Emergencies (SAGE), Academy of Science of South Africa (ASSAf).

Switzerland

Past

2003	<u>Guest lecturer:</u> 5 th Course on International Law of Armed Conflict organized by the International Committee of Military Medicine, Spiez, Switzerland, August 2003.
2005	<u>Guest lecturer:</u> 7 th Course on International Law of Armed Conflict organized by the International Committee of Military Medicine, Spiez, Switzerland, August 2005.
2006	<u>Guest lecturer:</u> 8 th Course on International Law of Armed Conflict organized by the International Committee of Military Medicine, Spiez, Switzerland, August 2006.

Present

<u>2002-current</u>	<u>Member:</u> International Ethics Review Board, Médecins Sans Frontières International, Geneva, Switzerland
<u>2023-current</u>	<u>Consultant:</u> World Health Organisation, Geneva, Switzerland

Canada

Past

- 2005-2011 Co-Director: Ethical, Social, and Cultural Issues Advisory Service to the Bill and Melinda Gates Foundation's Grand Challenges in Global Health Initiative, McLaughlin-Rotman Centre for Global Health, University Health Network and University of Toronto, Toronto, Canada.
- 2011-2013 Senior Bioethics Researcher: Sandra Rotman Centre, University Health Network and University of Toronto, Toronto, Canada
- 2014-2015 Senior Consultant: Centre for Ethical, Social, Cultural (ESC) Risk, St Michael's Hospital, Toronto, Canada.

Current

- 2004-present Adjunct Professor: Dalla Lana School of Public Health and Joint Centre for Bioethics, University of Toronto, Toronto, Canada.
- 2013-present Associate Member (graduate studies): Institute of Medicine, University of Toronto, Toronto, Canada.

United States

Past

- 2012-2023 Co-chair: HIV Prevention Trial Network (HPTN) Ethics Working Group (Family Health International [FHI] 360, Durham, NC, USA, serves as the leadership and operations center for the HPTN).

Current

- 2023-current Chair: HIV Prevention Trial Network (HPTN) Ethics Working Group (Family Health International [FHI] 360, Durham, NC, USA, serves as the leadership and operations center for the US NIH-sponsored HPTN).

Department and University Committees

South Africa

Past

- 1999-2002 Member (or alternate): Institutional Review Board / Research Ethics Committee, Nelson R. Mandela School of Medicine, University of Natal, Durban.
- 2000 Prosecutor / Defender: University of Natal Student Disciplinary Court.
- 2000-2001 Law Faculty Representative: Board of the Faculty of Community and Development Disciplines, University of Natal, Durban.
- 2000-2001 Law Faculty Representative: Traffic Working Group, University of Natal, Durban.
- 2001 Member: Publicity Committee, Howard College School of Law, University of Natal, Durban.
- 2004-2005 Member: Working Group: Developing Consolidated Research Policies for the University of KwaZulu-Natal.
- 2004-2006 Chairperson: CAPRISA Financial Conflicts of Interests Committee.

Current

- 2007-current Ad-hoc Special Advisor: Biomedical Research Ethics Committee, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban.

Teaching Experience and Responsibility

South Africa

Past

- 1996 Tutor: Department of Public Law, University of Natal, Durban (3 times weekly per course, full academic year) for *Interpretation of Statutes* [second year B.Proc. and 3rd year Legal Studies students]; and *Administrative Law* [final year B.Proc. students].
- 1997 Tutor: Department of Public Law, UND for *Human Rights* (twice weekly for full semester) to final year post-graduate LLB students; *Constitutional Law* (thrice weekly to final year Legal Studies and second year B.Proc. students); *Administrative Law* (twice weekly to final year graduate LLB students).
- 1997 Lecturer: Department of Business Law, University of Natal, Durban, (4 times weekly x 3 weeks {quarter of total course load}, second semester) for *Commercial Law 1B* [first year Commerce students].
- 1997 Lecturer: Alternative Access Programme, Innovation Centre, University of Natal, Durban, (4 times weekly x 3 weeks, {quarter of total course load}) for *Commercial Law 1B* [first year students in Advanced Diploma in Business Science bridging program].
- 1998 Lecturer: Department of Public Law, University of Natal, Durban: *Constitutional Law* (10 lectures per semester to final year BA undergraduate students); *Administrative Law* (10 lectures per semester to final year LLB graduate students); *Legal Diversity (Roman Law)* (10 lectures first semester to second year LLB undergraduate students); *Introduction to the Study of Laws* (26 interactive lectures first semester x 2 classes of first year LLB undergraduate students); *Specific Offences* (13 lectures first semester to undergraduate LLB students); *Legal Method* (10 lectures first semester to second year BA undergraduate students); *Foundations to the Study of Law* (26 interactive lectures second semester to 2 x classes of first year LLB undergraduate students).
- 1999-2004 Senior Lecturer: *Bioethics* (Course founder [1999] and Course Director: 26 lectures second semester {full course load} to undergraduate nursing and law students), *Bioethics and the Law* (Course founder [2000] and Course Director: 13 x two hour seminars second semester {full course load} to multidisciplinary graduate students; supervisor for LLM research projects / dissertations); *Internet and E-Commerce Law* (Course founder [2001] and Course Director: 7 x two hour seminars first semester to graduate students; ad-hoc sponsor/supervisor for LLM research projects / dissertations on topics pertaining to *Bioethics and the Law* and/or *Internet Law*); *Teaching Legal Skills* (Course Co-founder [1999]; Coordinator/Supervisor: 13 lectures per semester {half course load} to final year students); *Insurance and Agency* (Course Director: 20 lectures second semester to final year students); *Commercial Law 2A* and *Commercial Law 2B* (Course Director; 26-39 lectures {quarter of total course load} per semester).
Course Director: *Bioethics and the Law* (13 x two hour seminars to Master of Social Work (MSW) graduate students; sponsor/supervisor for LLM/MSW research projects pertaining to Bioethics and Social Work);
- 2004-2012 Course Director: *Bioethics* (26 lectures to undergraduate nursing, biomedical science and law students);
- 2004-2006 Sponsor/supervisor of CAPRISA bioethics doctoral [PhD] fellows 2004-2006: Ms Michelle Govender and Ms. Nilam Reddy, both registered with the Howard College School of Law, University of KwaZulu-Natal, Durban; Dr Aceme Nyika (post-doctoral fellow)

Current

- 2000-present **Course Director and dissertation supervisor:** *Bioethics and the Law* (13 x two hour seminars to multidisciplinary graduate students; sponsor/supervisor for LLM research projects / dissertations pertaining to Bioethics);
Post-graduate sponsor/supervisor: Howard College School of Law (sponsor/supervisor of LLD graduate [Prof. Yusuf Vawda, Howard College School of Law, University of KwaZulu-Natal, 2005-2011; graduated 2011]; Co-supervisor of PhD candidate [Ms Caron Jack, Nelson R. Mandela Medical School, 2008-present]; co-supervisor of PhD candidate [Dr Ruben Naidoo, Nelson R. Mandela Medical School, 2009-2013; graduated 2014];
Course Director: *Introduction to Medical Bioethics* (multidisciplinary graduate students enrolled for a post-graduate Diploma in HIV Management, Faculty of Medicine, Nelson Mandela School of Medicine);
Guest lecturer: MSc. in epidemiology and biostatistics (2 lectures on public health ethics to post-graduate multidisciplinary students, Faculty of Health Sciences).
- 2011-present **Course lecturer:** Advanced Research Ethics Training in Southern Africa (ARESA) Postgraduate Diploma in Health Research Ethics, University of Stellenbosch, Cape Town, South Africa.

Switzerland

Past

- 2003 **Guest lecturer:** *International humanitarian law and medical ethics* (5th Course on International Law of Armed Conflict organized by the International Committee of Military Medicine, Spiez, Switzerland, August 2003: plenary address to student body and observer in other class sessions).
- 2005 **Guest lecturer:** *International humanitarian law and medical ethics* (7th Course on International Law of Armed Conflict organized by the International Committee of Military Medicine, Spiez, Switzerland, August 2005: plenary address to student body and observer in other class sessions).
- 2006 **Guest Lecturer:** *International humanitarian law and medical ethics* (8th Course on International Law of Armed Conflict organized by the International Committee of Military Medicine, Spiez, Switzerland, August 2006: plenary address to student body).

Canada

- 2004-present **Adjunct Professor:** Joint Center for Bioethics and Dalla Lana School of Public Health, University of Toronto (guest lecturer on various courses at the Joint Center for Bioethics; ethics internship supervisor to MD candidate, Andrew Pinto, February 2005; graduate supervisory committee member to MSc/PhD candidate, Billy-Jo Hardy, 2007-2011).
- 2008-2013 **Course Director:** MSC 3006Y Independent Study (graduate course, Joint Centre for Bioethics, University of Toronto).
- 2009-present **Course Director:** Global Health Governance (core module of the graduate certificate in Global Health for medical residents and fellows, Global Health Education Initiative, Postgraduate Medical Education, Faculty of Medicine, University of Toronto).
- 2023-present **Course Director:** Planetary Health and Global Health Ethics (graduate course, Dalla Lana School of Public Health, University of Toronto).

Appointments, memberships, and consultancies

South Africa

Past

1998-2000	<u>Member</u> : Independent Medico-Legal Unit, Durban.
2000-2002	<u>Member</u> : HIV Post-Exposure Prophylaxis Group, Durban.
1999-2003	<u>Member</u> : Research Ethics Committee, Medical School, University of Natal
1999-2004	<u>Member</u> : KwaZulu-Natal Bioethics Reference Group.
2001	<u>Member</u> : proposed drafting sub-committee, South African Medicine Control Council (MCC) Clinical Trials Ethics Sub-Committee (to draft the definition of 'post-trial treatment' / long-term access to post-trial treatment) [inactive to date].
2003	<u>Member</u> : South African National Department of Health Taskforce on the revision of the National Health Act and its associated regulations pertaining to blood and tissue samples, therapeutic human cloning, and stem cell research in South Africa.
2004-5	<u>Clinical ethics trainer / consultant</u> : King George V Hospital, Durban, South Africa.
2004-2009	<u>Member</u> : Scientific Advisory Board, Aurum Institute for Health Research.
2005	<u>Rapporteur</u> : UNAIDS Southern and Eastern African Regional Consultation: Creating effective partnerships for clinical trials.
2005-2006	<u>Chairperson</u> : Clinical Ethics Committee, Resolution Health Medical Aid Scheme.
2007-2010	<u>Member</u> : Biomedical Research Ethics Committee, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban.
2008-09;18	<u>Member</u> : Justice and Constitutional Development Advisory Committee on Health Law, South African Law Reform Commission (Project 25 – Statutory Law Revision - Redundancy, Obsolescence and Constitutionality of Health Legislation).
2008-2012	<u>Member</u> : Research Ethics Committee, McCords Hospital, Durban.
2013	<u>Chair</u> : Social Science and Human Rights track, 6 th South African National AIDS Conference.
2004-2015	<u>Member</u> : Columbia University - Southern Africa Fogarty AIDS International Training and Research Program (AITRP) Scientific Advisory Committee.
2013-2018	<u>Board Member and Legal Representative</u> : International Network of Religious Leaders Living with or Personally Affected by HIV and AIDS (INERELA+)
2014-2015	<u>Member</u> : Academy of Science of South Africa (ASSAf) Expert Panel on Diversity in Human Sexuality
2014-present	<u>Member</u> : KwaZulu-Natal TB/ Drug-resistant TB Technical Forum Sub-committee on Legal and Ethical Issues on TB and Drug-resistant TB
2016-2018	<u>Member</u> : Human Research Ethics Committee, South African Medical Research Council.
2017-2018	<u>Member</u> : International Council of Science (ICSU) National Board of South Africa.
2004-2019	<u>Member</u> : Research Ethics Committee, South African Human Sciences Research Council.
2010-2020	<u>Special Advisor</u> : Biomedical Research Ethics Committee, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban.

Active/current

<u>2012-present</u>	<u>Member</u> : South African National AIDS Council (SANAC) Technical Task Team on Ensuring Protection of Human Rights and Improving Access to Justice.
<u>2014-present</u>	<u>Member</u> : KwaZulu-Natal TB/ Drug-resistant TB Technical Forum.
<u>2019-present</u>	<u>Member</u> : Academy of Sciences of South Africa (ASSAf) Consensus Study Panel: Ethical, Legal and Social Issues related to Gene Therapy: A South African perspective

2020-present Member: Protection of Personal Information Act (POPIA) Steering Committee to guide the development of the POPIA Code of Conduct for Research.

International

Past

2005 Reviewer on Ethical, Social, and Cultural Issues: short-listed recipients of the Grand Challenges in Global Health Initiative, Bill and Melinda Gates Foundation.

2005-2010 Member: International Therapeutic Data Safety Monitoring Board (Africa), National Institutes of Health, USA.

2008-2013 Member: International Association of Humanitarian Medicine (membership by invite only)

2008-2010 Member: World Health Organisation Task Force on Addressing Ethical Issues in TB Control Programmes.

2009-2017 Member: The Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health (MAL-ED) Study Bioethics Advisory Committee, Foundation for the National Institutes of Health, USA.

2012 Member: World Health Organisation Pandemic Flu Expert Consultant Group

2012 Consultant: United Nations Interregional Crime and Justice Research Institute (UNICRI).

2012-13 Member: World Health Organisation Consolidated Antiretroviral Treatment (ART) Guideline Development Group (Group 4: "Programmatic guidance").

2012 Consultant: World Health Organisation International Consultation on Ethical Considerations in Pre-Exposure Prophylaxis.

2012-13 Consultant: World Health Organisation 2013 Guidance for HIV Testing and Counseling (HTC) for adolescents and treatment and care for adolescents living with HIV: Recommendations for a public health approach.

2012-2014 Contractor: World Health Organisation Guidance on ethical considerations in planning and reviewing research studies on sexual and reproductive health in adolescents

2013-2014 Consultant: Considerations regarding consent in vaccinating children and adolescents between 6 and 17 years old.

2014 Consultant: World Health Organisation Third Global WHO Consultation on Strategic use of ARVs: Implementation Science to Inform Future ARV Guidelines.

2014 Consultant: WHO/UNAIDS Consultative Meeting on HIV Testing in the Context of HIV Surveillance

2015 Contractor: The Special Programme for Research and Training in Tropical Diseases (WHO-TDR) - Developing a module on community engagement in implementation research

2016 Contractor: UNICEF / Sexual and Reproductive Rights Africa Trust (SAT). Ethical, Social, and Cultural Factors that hinder adolescents' access to sexual and reproductive healthcare services: International Review

2017 Consultant: World Health Organisation Scoping meeting on the ethics of vector-borne disease.

2018 Member: PHASES (Pregnancy and HIV/AIDS - Seeking Equitable Study) Working Group.

2018-2020 Consultant and Contractor: World Health Organisation International Consultation on Ethics and Vector Borne Diseases.

2018-20 Member: World Health Organisation Guideline Development Group. Updated recommendations on safe male circumcision for HIV prevention and related service delivery for adolescent boys and men in generalized HIV epidemics.

2019	<u>Member</u> : World Health Organisation Expert Group on Ethical Issues in Research & Programming with Vulnerable Young Adolescents.
2019	<u>Member</u> : World Health Organisation Expert Group on Ethics of Maternal Immunization.
2020	<u>Member</u> : WHO Working Group on the Ethics and the use of Artificial Intelligence for the COVID-19 response.
2020	<u>Member</u> : World Health Organisation Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation.
2021	<u>Consultant</u> : WHO Consultative Meeting on a Global Guidance Framework to Harness the Responsible use of Life Sciences.
2021	<u>Contractor</u> : Emergency contract to support the work of the WHO Health Ethics & Governance Unit (the Unit) on Ethics & COVID-19.
2021	<u>Consultant</u> : World Health Organisation Guidance on human biomonitoring in artisanal and small-scale gold mining: ethical and scientific principles
2020-2022	<u>Member</u> : World Health Organisation Access to COVID-19 Tools (ACT) Accelerator Ethics & Governance Working Group / COVID-19 Ethics and Governance Working Group.
2020	<u>Advisor</u> : World Health Organisation Global Health Foresight Function.
2020-2023	<u>Member</u> : World Health Organisation Ad Hoc Research Ethics Review Committee for COVID-19.
2021	<u>Member</u> : World Health Organisation / International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) Trials in Pregnant Women' Working Group.
2021-2023	<u>Member</u> : World Health Organisation COVID-19 Ethics and Governance Working Group.

Active/Current

<u>2002-present</u>	<u>Member</u> : International Ethics Review Board, Médecins Sans Frontières (Doctors Without Borders).
<u>2005-present</u>	<u>Member</u> : External Advisory Group on Publication Ethics and Competing Interests, <i>Public Library of Sciences (PLoS) Medicine</i> .
<u>2008-present</u>	<u>Member</u> : International Advisory Board of the <i>Journal of Bioethical Inquiry</i>
<u>2009-present</u>	<u>Member</u> : External Advisory Committee, ENCORE (Evaluation of Novel Concepts in Optimization of anti-Retroviral Efficacy) Trial, National Centre in HIV Epidemiology and Clinical Research (NCHECR), University of New South Wales, Australia.
<u>2011-present</u>	<u>Member</u> : Critical Path for TB Regimens (CPTR) high-level Advisory Committee.
<u>2012-present</u>	<u>Member</u> : HPTN Chairs and Co-chairs Science Committee
<u>2014-present</u>	<u>Member</u> : PLoS One Human Research Advisory Group
<u>2014-present</u>	<u>Board Member</u> : African Centre for Innovation and Leadership
<u>2014-present</u>	<u>Member</u> : PLoS One Editorial Board
<u>2014-present</u>	<u>Member</u> : HIV Vaccine Trial Network (HVTN) Efficacy Trials Working Group
<u>2015-present</u>	<u>Member</u> : International AIDS Society Towards an HIV Cure Committee
<u>2015-present</u>	<u>Member</u> : External Advisory Group – ICAP (International Center for AIDS Care and Treatment Programs) Population-based HIV Impact Assessment (PHIA) Project, Columbia University, New York City, USA
<u>2016-present</u>	<u>Member</u> : Programme Committee, International AIDS Society Towards an HIV Cure Symposium
<u>2017-present</u>	<u>Member</u> : World Health Organisation International Health Regulations 'Public Health Emergency of International Concern' (PHEIC) Expert Roster
<u>2019-present</u>	<u>Member</u> : Scientific Advisory Committee, Association for Responsible Research and Innovation in Genome Editing (ARRIGE), Centre for Interdisciplinary Research (CRI), Paris, France.

<u>2019-present</u>	<u>Member:</u> Global Early Adolescent Study Advisory Board, Johns Hopkins University, Baltimore, USA.
<u>2019-present</u>	<u>Member:</u> African Academy of Sciences Clinical Trials Community (CTC) Advisory Committee.
<u>2020-present</u>	<u>Member:</u> Scientific Committee, Association for Responsible Research and Innovation in Genome Editing (ARRIGE), Paris, France
<u>2020-present</u>	<u>Member:</u> Working Group on Gene Drives, Association for Responsible Research and Innovation in Genome Editing (ARRIGE), Center for Interdisciplinary Research (CRI), Paris, France.
<u>2020-present</u>	<u>Member:</u> Scientific Advisory Board / Steering Committee, DATURA (Determination of Adequate Tuberculosis Regimen in Adults and adolescents hospitalised with HIV-associated severe immune suppression) Trial (funded by the European and Developing Countries Clinical Trials Partnership (EDCTP) and the French ANRS (National Agency for Research on AIDS & Viral Hepatitis).
<u>2020-present</u>	<u>Member:</u> World Health Organisation Expert Group on Ethics & Governance of Artificial Intelligence for Health.
<u>2020-present</u>	<u>Member:</u> World Health Organisation Technical Advisory Group (TAG) for Emergency Use Listing.
<u>2021-present</u>	<u>Member:</u> International AIDS Society Global Scientific Cure Strategy (GCS) Steering Committee.
<u>2022-present</u>	<u>Member:</u> World Health Organisation Ethics & Monkeypox Working Group
<u>2023-present</u>	<u>Member:</u> WHO Expert Group on the Ethics & Governance of Infectious Disease Outbreaks and Other Emergencies of Public Health Importance.
<u>2023-present</u>	<u>Member:</u> Steering Committee, University of California-Berkeley School of Public Health Forum for Collaborative Research.
<u>2023-present</u>	Scientific Advisory Board, Precision Action for Rifampicin-Resistant TB (PARR TB) study.
<u>2024-present</u>	<u>Member:</u> Long Acting Pre-exposure Prophylaxis (LA PrEP) in pregnancy and lactation working group, University of California-Berkeley School of Public Health Forum for Collaborative Research.
<u>2024-present</u>	<u>Member:</u> Scientific Advisory Board: Integrating Trauma-Informed Research in Assessment of Young Women Engaged in HIV Cure (Post-Intervention Control) Trial with an Analytical Treatment Interruption in Durban, South Africa

Other professional roles

Manuscript review responsibilities

2001;'09;'12	Manuscript Reviewer: <i>Developing World Bioethics</i>
2003-current	Manuscript Reviewer: <i>Lancet; Lancet Infectious Diseases; Lancet Global Health</i>
2004	Manuscript Reviewer: <i>BMC Medical Education</i>
2004	Manuscript Reviewer: <i>AIDS Law Project</i> , Johannesburg
2005	Manuscript Reviewer: <i>Health Policy</i>
2005	Manuscript Reviewer: <i>International Journal of Equity in Health</i>
2005	Manuscript Reviewer: <i>Nursing Ethics</i>
2005-2006	Manuscript Reviewer: <i>Hastings Center Report</i>
2005-2006	Manuscript Reviewer: <i>South African Journal of Science</i>
2005-2017	Manuscript Reviewer: <i>PLoS Medicine</i>
2006	Manuscript Reviewer: <i>South African Journal of Human Rights</i>
2006; 2009	Manuscript Reviewer: <i>Stellenbosch Law Review</i>
2006-2008	Manuscript Reviewer: <i>African Journal of AIDS Research</i>
2007	Manuscript Reviewer: <i>BMC International Health and Human Rights</i>
2009	Manuscript Reviewer: <i>Public Health Ethics</i>
2010	Manuscript Reviewer: <i>Health Education Research</i>
2012;13	Manuscript Reviewer: <i>Journal of Medical Ethics</i>

2013 Manuscript Reviewer: *Public Health Nutrition*
2014-current Academic Editor: *PLoS One*

Grant and Peer Review Responsibilities

2001 Grant reviewer: National Research Foundation, South Africa.
2005 Grant reviewer: Bill and Melinda Gates Foundation, USA.
2008 Grant reviewer: Wellcome Trust, UK.
2009 Grant reviewer: Genome Canada, Canada.
2009 Grant reviewer: Social Sciences and Humanities Research Council of Canada, Canada.
2010 Grant reviewer: Wellcome Trust, UK.
2011 Grant reviewer: Wellcome Trust, UK.
2012-current Grant reviewer: National Research Foundation, South Africa.
2012 Grant reviewer: Central Ontario, Ontario Centres of Excellence, Canada
2013-current Grant reviewer: National Research Foundation, South Africa
2013-current Peer reviewer: National Research Foundation, South Africa
2020-23 Grant reviewer: Swiss National Research Foundation

Honours

1997 Awarded University of Natal Graduate Scholarship.
1998 Awarded Master of Laws [LLM] (Natal) *cum laude*.
2002 Awarded Fogarty Fellowship, Southern African Fogarty AIDS International Training and Research Programme, United States National Institutes of Health (NIH) Fogarty International Centre.
2003 Awarded Master of Health Sciences [MHSc] (Toronto) degree with A+ (90-100%) average.
2004 Biographical profile solicited and selected for inclusion in 22nd edition of *Marquis Who's Who in the World - 2005* (Marquis Who's Who, New Jersey, USA) on the basis of outstanding scientific output and accomplishments in 2004.
2005 Named amongst the *2000 Outstanding Intellectuals of the 21st Century – 2005* (International Biographical Centre, Cambridge, UK) on the basis of outstanding scientific output and achievements in 2004/2005.
2005 Named in inaugural list of *Leading Educators of the World - 2005* (International Biographical Centre, Cambridge, UK) on the basis of outstanding academic output and achievements in 2004/2005.
2009 Awarded a Y-rating by the National Research Foundation, South Africa.
2009 Biographical profile solicited and selected for inclusion in the *Global Directory of Who's Who - 2009* (Global Directory of Who's Who, Holbrook, NY, USA) on the basis of outstanding scientific output and accomplishments in 2008/2009.
2010 Rated amongst the top 15 researchers at the University of KwaZulu-Natal, South Africa, based on 2009 research output.
2011 Elected by the Academy of Sciences of South Africa (ASSAf) through a competitive process as one of the 20 Founding Members of the Young Academy of Science of South Africa (SAYAS).
2011 Elected as inaugural Co-Chair of the Young Academy of Science of South Africa (SAYAS) by the General Assembly of SAYAS.
2012 Recognised as an international thought leader and global 'New Champion', and invited to participate in the World Economic Forum (Summer Davos), Tianjin, China, September 2013.
2012 Re-elected Co-Chair of the Young Academy of Science of South Africa (SAYAS) by the SAYAS General Assembly.

- 2013 Global Health Education Initiative Award of Excellence (Global Health Education Initiative, Postgraduate Medical Education, Faculty of Medicine, University of Toronto, Canada).
- 2013 Recognised as an international thought leader and invited to participate in the World Science Forum, Rio de Janeiro, Brazil, November 2013.
- 2014 Represented the South African government (Department of Science and Technology) at the United Nations World Youth Conference, Colombo, Sri Lanka, May 2014.
- 2015 Global Health Education Initiative Award of Excellence (Global Health Education Initiative, Postgraduate Medical Education, Faculty of Medicine, University of Toronto, Canada).

Research Output

Publications

* indicates Singh JA as first author

Published articles

1999

1. * Singh JA. Freedom of Expression: The Constitutionality of a Ban on Human Cloning in the Context of a Scientist's Guaranteed Right to Freedom of Scientific Research. *The Journal of Contemporary Roman-Dutch Law (THRHR)* 1999; 62; 4: 577-591.

2000

2. * Singh JA. Preventative Diplomacy as a Mechanism for Resolving Rates Disputes. *Butterworths Property Law Digest* 2000; 4; 1: 7-13.

2001

3. Dada MA and Singh JA. Medico-legal Aspects of Molecular Medicine. *East African Journal of Molecular Medicine* 2001; 78; 7. Supplement.

4. * Singh JA. The Ethics of HIV Vaccine Trials: International Guidelines. *AIDS Legal Quarterly* 2001; September: 7.

2002

5. * Singh JA. The Ethics of Cosmetic Dermatology' *South African Dermatology Review*. 2002; 2; 3: 49-51.

6. * Singh JA. and Singer P.A. Isolationism is not the answer to Bio-terrorism. *Nature* 2002; 420: 605.

2003

7. * Singh JA. Work on non-lethal weapons should be limited too. *Nature* 2003; 422: 122.

8. * Singh JA and DePellegrin TL. Images of war and medical ethics. *British Medical Journal* 2003; 326: 774-775.

9. * Singh JA and DePellegrin TL. Images of war and medical ethics. *BMJUSA* 2003; 3: 335-336. [Republished under "Debate and Education" section]

10. * Singh JA and DePellegrin TL. The authors respond. *BMJUSA* 2003; 3: 336. [letter]

11. * Singh JA SARS, a challenge from the South. *Nature* 2003; 423: 585.

12. Lemmens T and Singh JA. Moral duty but also self-interest require a greater commitment to the South. *Canadian Bioethics Society Newsletter* 2003; 8 (2) 5-7.

13. * Singh JA. American physicians and dual loyalty obligations in the "war on terrorism". *BMC Medical Ethics* 2003; 4:4: 1-10.

14. * Singh JA. Military tribunals at Guantanamo Bay: dual loyalty conflicts. *Lancet* 2003; 362: 573.
15. * Singh JA, Nkala B, Amuah, E, Mehta N, Ahmad N. The ethics of nurse-poaching from the developing world. *Nursing Ethics* 2003; 10 (6): 667-671.
16. * Singh JA. Is donor aid allocation to Iraq fair? *Lancet* 2003; 362: 1672-3.

2004

17. * Singh JA. Politics in medical journals: author reply. *Lancet* 2004; 363: 328-329.
18. * Singh JA. Health research and human rights in South Africa. *Lancet* 2004; 363: 1393.
19. * Singh JA. Ten year review of research in South Africa. *Nature* 2004; 428: 891.
20. Lemmens T, Sprumont D, Nys H, Singh JA, Cranley Glass. CIOMS' placebo rule and the promotion of negligent malpractice. *European Journal of Health Law* 2004; 11(2): 153-174.
21. * Singh JA. Genocide: burden of proof and inaction is costing lives in Sudan. *Lancet* 2004; 364: 230-231.
22. * Singh JA. Standards of care in the antiretroviral rollout world. *Lancet* 2004; 364: 920-921.
23. * Singh JA. The implications of the National Health Act for research in South Africa. *South African Research Ethics Committee Newsletter* 2004; Vol. 1(2) 6-8.
24. * Singh JA. Why AIDS in South Africa threatens stability and economic growth in other parts of Africa. *Lancet* 2004; 364: 1919-1921.

2005

25. * Singh JA and Mills EJ. The abandoned trails of pre-exposure prophylaxis for HIV: what went wrong? *PLoS Medicine* 2005; 2(9):e234: 0101-0104.
26. * Singh JA. Zimbabwe: health and human rights should trump African solidarity. *Lancet* 2005; 366: 964-966.
27. Mills JM, Singh S, Singh JA, Orbinski J, Warren M, Upshur R. Early lessons from HIV prevention trials that stopped. Designing research in vulnerable populations. *British Medical Journal* 2005; 331; 1403-1406.
28. * Singh JA, Govender M, and Reddy N. South Africa a decade after apartheid: realising health through human rights. *Georgetown Journal of Poverty Law and Policy* 2005; XII; 3: 355-388.

2006

29. * Singh JA. How over-protectionism can evidence unethical outcomes: examples from South Africa. *Research Ethics Review* 2006; 2(2): 63-66.
30. * Singh JA, Abdool Karim SS, Abdool Karim Q, Misana K, Williamson C, Gray C, Govender M, Gray A. Enrolling adolescents in research on HIV and other sensitive issues: lessons from South Africa. *PLoS Medicine* 2006; 3(7): e180.
31. * Singh JA. The vital importance of implementation ethics. *The Hastings Center Report*. May/June 2006; 3.

32. Chan A, Upshur R, Singh JA, Altman Gherzi D, Chapuis F, Altman DG. Waiving confidentiality for the greater good? *British Medical Journal* 2006; 332:1086-1089.

33. Strode A, Slack C, Singh JA, Grant C, Stobie M. Balancing protection and empowerment in the regulation of child research: some South African reflections. *Asia-Pacific Biotech News* 2006: Vol. 10; No. 11: 588-591.

34. * Singh JA. Post 9/11: Treating war detainees and terror suspects: legal and ethical responsibilities of physicians serving in the armed forces. *JIMASA* 2006; 13;1: 2-13.

2007

35. * Singh JA, Upshur R, Padayatchi N. XDR-TB in South Africa: No time for denial or complacency. *PLoS Med* 2007; 4(1): e50. doi:10.1371/journal.pmed.0040050.

36. Strode AE, Slack CM, Wassenaar DR, Singh JA. One step forward, two steps back – requiring ministerial approval for all ‘non-therapeutic’ health research involving minors. *SAMJ* 2007; 97; 3: 200-202.

37. * Singh JA. Isolating TB patients: prevention better than cure. *SciDevNet*; July 4, 2007. Available online: <http://www.scidev.net/en/opinions/isolating-tb-patients-prevention-better-than-cure.html>

38. * Singh JA, Govender M, Mills E. Do human rights matter to health? *Lancet* 2007; 370: 521-526.

39. Singer PA, Taylor AD, Daar AS, Upshur REG, Singh JA, Lavery J. Grand Challenges in Global Health: The Ethical, Social and Cultural Program. *PLoS Medicine* 2007;4(9): e265. doi:10.1371/journal.pmed.0040265.

40. Berndtson K, Daid T, Tracey SE, Bhan A, Cohen E, Upshur REG, Singh JA, Daar AS, Lavery JV and Singer PA. Grand Challenges in Global Health: ethical, social, and cultural issues based on key informant perspectives. *PLoS Medicine* 2007;4(9): e268. doi:10.1371/journal.pmed.0040268.

41. Bhan A, Singh JA, Upshur REG, Singer PA, and Daar AS. Grand Challenges in Global Health: Engaging civil society organizations in biomedical research in developing countries. *PLoS Medicine* 2007;4(9):e272. doi:10.1371/journal.pmed.0040272.

42. Tindana PO, Singh JA, Tracy SE, Upshur REG, Daar AS, Singer PA, Frohlich J, Lavery JC. Grand Challenges in Global Health: Community engagement in research in developing countries. *PLoS Medicine* 2007;4(9):e273. doi:10.1371/journal.pmed.0040273.

43. * Singh JA. Treating war detainees and terror suspects: legal and ethical responsibilities of military physicians. *Military Medicine* 2007;172; Dec Supplement:15-21.

2008

44. * Singh JA and Daar AS. The 20-year African biotech plan. *Nature Biotechnology* 2008; 26(3):272-274.

45. * Singh JA. Eugenics in apartheid South Africa. *Endeavour* 2008; 32(1) 5-9.

46. Cohen ER, Masum H, Berndtson K, Saunders V, Hadfield T, Panjwani D, Persad DL, Minhas GS, Daar AS, Singh JA, Singer PA. Public engagement on global health challenges. *BMC Public Health*. 2008 May 20;8:168. <http://www.biomedcentral.com/1471-2458/8/168>

47. * Singh JA. The ethics and legality of traditional healers performing HIV testing. *Southern African Journal of HIV Medicine* Summer 2008: 23-26.

2009

48. Upshur, Singh JA, Ford N, Apocalypse or Redemption: Responding to XDR-TB. *Bull World Health Organ* 2009;87:000–000 | doi:10.2471/BLT.08.051698.

49. Lavery JV, Ridzon R, Singh JA, Slutsky AS, Anisko JJ, Singer PA. In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs? *PLoS Medicine* 6(6): e1000071. doi:10.1371/journal.pmed.1000071.

50. * Singh JA, Bandewar S, Singer PA. Sex, gender, and health biotechnology: points to consider. *BMC International Health and Human Rights* 2009, 9:15 doi:10.1186/1472-698X-9-15.

51. * Schopper D, Upshur R, Matthys F, Singh JA, Bandewar SS, et al. (2009) Research Ethics Review in Humanitarian Contexts: The Experience of the Independent Ethics Review Board of Médecins Sans Frontières. *PLoS Med* 6(7): e1000115. doi:10.1371/journal.pmed.1000115

52. * Singh, J.A. Research and legal liability. *Acta Tropica* 112S (2009) S71–S75.

53. * Singh JA. Using the courts to challenge irrational research policies and decisions. *Acta Tropica* 112S (2009) S76–S79

54. * Singh JA and Daar AS. Data sharing and research output governance in multi-country, multi-institutional collaborations. *The Human Genome Organisation Journal* 2009: DOI 10.1007/s11568-009-9130-5.

2010

55. * Singh JA. Organ transplantation between HIV-infected patients. *Lancet* 2010;375: 442-443.

56. * Singh, JA, Daar, AS, and Singer, PA. Shared principles of ethics on complementary feeding products for infants and young child nutrition in the developing world. *BMC Public Health* 2010, 10:321doi:10.1186/1471-2458-10-321.

57. * Singh JA. A commentary on Jaffer and Hope's proposed ethical framework. *Public Health Ethics* 2010; 3(3): 303–304.

2011

58. * Singh JA. The Challenge of Discharging Research Ethics Duties in Resource-Constrained Settings. *PLoS Med* 2011; 8(3): e1000421. doi:10.1371/journal.pmed.1000421 (also published in the WHO/PLoS World Health Report 2012: No Health Without Research collection. <http://www.ploscollections.org/article/browse/issue.action?issue=info:doi/10.1371/issue.pcol.v01.i09>)

59. Kraemer JD, Cabrera OA, Singh, JA, Depp TB, Gostin LO. Public health measures to control tuberculosis in low-income countries: ethics and human rights considerations. *International Journal of Tuberculosis and Lung Disease* 2011;15(6):S19–S24.

60. Singh JA and Bhan A. The ethics of national tuberculosis programmes in low-income countries not rolling out Xpert® MTB/RIF. *International Journal of Tuberculosis and Lung Disease* 2011;15(12):1563.

2012

61. * Singh JA, Bhan A and Upshur R. TB management in India: public health, ethics, social considerations, and human rights. *Bioethical Inquiry* 2012 DOI 10.1007/s11673-012-9370-2.

62. * Singh JA. Why human health and health ethics must be central to climate change deliberations. *PLoS Med* 2012 9(6): e1001229. doi:10.1371/journal.pmed.1001229.

2013

63. * Singh JA. Antiretroviral resource allocation for HIV prevention. *AIDS* 2013, 27:863–865.

64. * Singh JA, Bhan A, and Upshur REG. Diagnosis of drug-resistant TB and provision of second line TB treatment in India: some ethics considerations. *IJME* 2013; 10(2): 110-114.

65. Naidoo K, Singh JA, Lalloo U. HIV/AIDS and admission to intensive care units: A comparison of India, Brazil and South Africa. *S Afr J HIV Med* 2013;14(1):15-16. DOI:10.7196/SAJHIVMED.887.

66. * Singh JA. Bigotry and Oppressive Laws in Africa Drive HIV in Men Who Have Sex with Men. *PLoS Med* 2013; 10(6): e1001471. doi:10.1371/journal.pmed.1001471.

67. * Singh JA. Why vulnerable young women at risk of HIV should be prioritized for access to preexposure prophylaxis. *AIDS* 2013; 27;DOI:10.1097/QAD.0b013e3283633ad4.

68. * Singh JA. India's regulatory reforms on compensation for clinical trial injuries and deaths: urgent need for revisiting *IJME* 2013 No 3 July-September 2013: 195-197.

69. Naidoo K, Singh JA, Lalloo U. Survey of ethical dilemmas facing intensivists in South Africa in the admission of patients with HIV infection requiring intensive care. *S Afr J Crit Care* 2013;29(1):28-32. DOI:10.7196/SAJCC.153.

70. Lavery JV, Green SK, Bandewar SVS, Bhan A, Daar A, Emerson CL, Masum H, Randazzo FM, Singh JA, Upshur REG, Singer PA. Addressing Ethical, Social and Cultural Issues in Global Health Research. *PLoS Negl Trop Dis* 2013; 7(8): e2227. doi:10.1371/journal.pntd.0002227.

71. Baltussen R, Mikkelsen E, Tromp N, Hurtig A, Byskov J, Olsen O, Baerøe K, Hontelez J, Singh JA, and Norheim O. Balancing feasibility, efficiency and equity of HIV treatment in South Africa - development of programmatic guidance. *Cost Effectiveness and Resource Allocation* 2013, 11:26.

72. Naidoo K, Singh JA, Lalloo U. Critical analysis of ICU/HC beds in South Africa: 2008 – 2009. *S Afr Med J* 2013;103(10):751-753. DOI:10.7196/SAMJ.6415.

2014

73. Mngadi KT, Frohlich J, Montague C, Singh JA, Nkomonde N, Mvandaba N, Ntombela F, Luthuli L, Karim QA, Mansoor L. Challenges with Participant Reimbursement: Experiences from CAPRISA 008 - A Post-trial Access Study. *AIDS Research and Human Retroviruses*. 2014;30(S1):A53.

2015

74. (Alphabetical, except for lead authors): Schopper D, Dawson A, Upshur R, Ahmad A, Jesani A, Ravinetto R, Segelid M, Sheel S, and Singh JA. Innovations in research ethics governance in humanitarian settings. *BMC Medical Ethics* 2015, 16:10 doi:10.1186/s12910-015-0002-3.

75. Baggaley R, Johnson C, Calleja JMG, Sabin K, Obermeyer C, Taegtmeier M, Zaba B, El-Hayek C and Singh JA. Routine feedback of test results to participants in clinic- and survey-based surveillance of HIV. *Bull World Health Organ* 2015;93:352–355 | doi: <http://dx.doi.org/10.2471/BLT.15.15303>.

76. * Singh JA. Humanitarian Access to Unapproved Interventions in Public Health Emergencies of International Concern. *PLoS Med* 2015: 12(2): e1001793. doi:10.1371/journal.pmed.1001793.

77. * Singh JA. How Bioethics Is Complementing Human Rights in Realizing Health Access for Clinical Trial Participants: The Case of Formative PrEP Access in South Africa. *Health and Human Rights Journal* 2015: 1(17): 58-62.

78. * Singh JA. Sustainable development goals: the role of ethics. *Sight and Life* 2015; 29(2): 56-61.

2016

79. * Singh JA. Ethical Issues to Consider in the Design of HIV Prevention Trials Involving Transgender People. *J Acquir Immune Defic Syndr* 2016;72:S252–S255.

80. Mann J, Pasternak AO, Chahroudi A, Singh JA and Ross AL. The latest science from the IAS Towards an HIV Cure Symposium. 16–17 July 2016, Durban, South Africa. *Journal of Virus Eradication* 2016; 2: 235–241.

81. (alphabetical, except for lead-authors) Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo YR, Kuritzkes D, Margolis D, Mellors J, Persaud D, Tucker JD, Barre-Sinoussi F; International AIDS Society Towards a Cure Working Group, Alter G, Auerbach J, Autran B, Barouch DH, Behrens G, Cavazzana M, Chen Z, Cohen ÉA, Corbelli GM, Eholié S, Eyal N, Fidler S, Garcia L, Grossman C, Henderson G, Henrich TJ, Jefferys R, Kiem HP, McCune J, Moodley K, Newman PA, Nijhuis M, Nsubuga MS, Ott M, Palmer S, Richman D, Saez-Cirion A, Sharp M, Siliciano J, Silvestri G, Singh JA, Spire B, Taylor J, Tolstrup M, Valente S, van Lunzen J, Walensky R, Wilson I, Zack J. International AIDS Society global scientific strategy: towards an HIV cure 2016. *Nat Med*. 2016 Aug;22(8):839-50. doi: 10.1038/nm.4108. Epub 2016 Jul 11.

82. Schopper D, Schwartz L, Kamaara E, Sheel S, Segelid MJ, Ahmad A, Dawson A, Singh JA, Jesani A, Upshur R. Research Ethics Governance in Times of Ebola. *Public Health Ethics* 2016; November: 1–13.

83. Gopichandran V, Luyckx VA, Biller-Andorno N, Fairchild A, Singh JA, Tran N, Saxena A, Launois P, Reis A, Maher D, Vahedi M. Developing the ethics of implementation research in health. *Implementation Science* 2016; 11:161.

2017

84. Roberts A, Paes de Andrade P, Okuma F, Quemada H, Savadogo M, Singh JA, James S. Results from the Workshop “Problem Formulation for the use of Gene Drive in Mosquitoes” *Am. J. Trop. Med. Hyg.*, 96(3), 2017, pp. 530–533. doi:10.4269/ajtmh.16-0726.

85. * Singh JA and SS Abdool-Karim. Trump's "global gag rule": Implications for human rights and global health. *Lancet Global Health*. Vol 5 April 2017. Available: [http://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X\(17\)30084-0.pdf](http://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(17)30084-0.pdf).

86. Mngadi KT, Singh JA, Mansoor LE, et al Undue inducement: a case study in CAPRISA 008 *Journal of Medical Ethics* 2017;0:1–5. doi:10.1136/medethics-2016-103414.

87. Pillay BJ and Singh JA. Mental capacity', 'sufficient maturity' and 'capable of understanding' in relation to children: how should health professionals interpret these terms? *South African Journal of Psychology*. 2017; 1–15. DOI: 10.1177/0081246317747148.

2018

88. James S, Collins FH, Eckhoff PA, Emerson CH, Godfray CJ, Gottlieb M, Greenwood B, Lindsay SW, Mbogo CM, Okumu FO, Quemada H, Savadogo M, Singh JA, Tountas KH, Touré, YT. Pathway to Deployment of Gene Drive Mosquitoes as a Potential Biocontrol Tool for Elimination of Malaria in Sub-Saharan Africa: Recommendations of a Scientific Working Group. *American Journal of Tropical Medicine & Hygiene* 2018;98(Suppl 6): 1–49. doi:10.4269/ajtmh.18-0083.

89. * Singh JA. The ethics of cosmetic dermatology revisited. *Dermatology Review* 2018; Annual edition: 21-26.

2019

90. Mahomed S, Padayatchi N, Singh JA, Naidoo K. Precision Medicine in Resistant Tuberculosis: Treat the correct patient, at the correct time, with the correct drug. *Journal of Infection* 2019; 78: 261–268.

91. * Singh JA, Siddiqi M, Parameshwar P, and Venkatraman C. World Health Organization Guidance on Ethical Considerations in Planning and Reviewing Research Studies on Sexual and Reproductive Health in Adolescents. *Journal of Adolescent Health* 2019; 64; 427e429.

92. Thizy D, Emerson C, Gibbs J, Hartley S, Kapiriri L, Lavery J, Lunshof J, Janine Ramsey J, Shapiro, J, Singh JA, Toe LP, Coche I, Robinson B. Guidance on stakeholder engagement practices to inform the development of area-wide vector control methods. *PLoS Negl Trop Dis* 2019; 13(4): e0007286. <https://doi.org/10.1371/journal.pntd.0007286>

93. * Singh JA. Informed consent and community engagement in open field research: lessons for gene drive science. *BMC Medical Ethics* (2019) 20:54. <https://doi.org/10.1186/s12910-019-0389-3>. Available: <https://bmcmethics.biomedcentral.com/articles/10.1186/s12910-019-0389-3>.

94. * Singh JA. Artificial Intelligence and global health: opportunities and challenges. *Emerg Top Life Sci* 2019; 3 (6): 741–746.

2020

95. * Singh JA and Moodley K. Critical care triaging in the shadow of COVID-19: Ethics considerations. *South African Medical Journal* 2020;110(5). Published online 16 April 2020. Accessible: <http://www.samj.org.za/index.php/samj/article/view/12907>

96. * Singh JA. COVID-19: Science and global health governance under attack. *South African Medical Journal* 2020;110(5):. DOI:10.7196/SAMJ.2020v110i5.14820. Published online 20 April 2020. Accessible: <http://www.samj.org.za/index.php/samj/article/view/12908>

97. * Singh JA. COVID-19: Mandatory institutional isolation v. voluntary home self-isolation. *South African Medical Journal* 2020;110(6):. DOI:10.7196/SAMJ.2020v110i6.14840. Published online 23 April 2020. Accessible: <http://www.samj.org.za/index.php/samj/article/view/12914>

98. * Singh JA. How South Africa's Ministerial Advisory Committee on COVID-19 can be optimised. *South African Medical Journal* 2020; Published online 14 May 2020. <https://doi.org/10.7196/SAMJ.2020>. v110i6.14911. Accessible:<http://www.samj.org.za/index.php/samj/article/view/12948>.

99. * Singh JA, Habib A, Jansen J. Freedom of speech and public interest, not allegiance, should underpin science advisement to government. *South African Medical Journal*. Published online 26 May 2020. <https://doi.org/10.7196/SAMJ.2020>. v110i7.14958. Accessible: <http://www.samj.org.za/index.php/samj/article/view/12954>.

100. * Singh JA. The case for why Africa should host COVID-19 candidate vaccine trials. *Journal of Infectious Diseases* 2020; DOI: 10.1093/infdis/jiaa303. Accessible: <https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiaa303/33341597/jiaa303.pdf>.

101. * Singh JA and Moodley K. The Critical Care Society of Southern Africa guidelines on the allocation of scarce critical care resources during the COVID-19 public health emergency in South Africa. Response by Singh and Moodley. *South African Medical Journal*. Published online 5 June 2020. <https://doi.org/10.7196/SAMJ.2020>. v110i8.15000. Accessible: <http://www.samj.org.za/index.php/samj/article/view/12986>.

102. * Singh JA, Bandewar SVS, Bukusi EA. The impact of the COVID-19 pandemic response on other health research. *Bulletin of the World Health Organisation* 2020 Sep 1;98(9):625-631. doi: 10.2471/BLT.20.257485. Epub 2020 Jul 6.

103. * Singh JA and Ravinetto R. COVID-19 therapeutics: how to sow confusion and break public trust during international public health emergencies. *Journal of Pharmaceutical Policy and Practice* 2020; 13:47. <https://doi.org/10.1186/s40545-020-00244-02020>.

104. * Singh JA. COVID-19 vaccine trials: duty of care and standard of prevention considerations. *Vaccine* 2020; 38: 7578–7580. <https://linkinghub.elsevier.com/retrieve/pii/S0264410X20313025>.

105. WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation (Members, ordered alphabetically after lead author: Krause PR, Fleming TR, Longini IM, Peto R, Beral V, Bhargava B, Cravioto A, Cramer J, Ellenberg SS, Figueroa JP, Halloran E, Henao-Restrepo AM, Ryan MJ, Levine MM, Nason M, Nohynek HM, Plotkin S, Rees H, Singh JA, Swaminathan S). Placebo-Controlled Trials of Covid-19 Vaccines - Why We Still Need Them. *New England Journal of Medicine*. December 2, 2020. DOI: 10.1056/NEJMp2033538. <https://www.nejm.org/doi/full/10.1056/NEJMp2033538>.

106. * Singh JA and Uphsur REG. The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials. *Lancet Infectious Diseases*. December 08, 2020. DOI: [https://doi.org/10.1016/S1473-3099\(20\)30923-3](https://doi.org/10.1016/S1473-3099(20)30923-3). [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(20\)30923-3/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30923-3/fulltext).

2021

107. Fidler S, Lewin S, Deeks S, Sogaard OS, Vanderkerckhove L, Collins S, Kelly D, Singh JA, Caskey M, Frater J. HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper. *Journal of Virus Eradication* 7 (2021) 100025. <https://doi.org/10.1016/j.jve.2020.100025>.

108. * Singh JA, Kochhar S, and Wolff J and the WHO ACT-Accelerator Ethics & Governance Working Group. Placebo use and unblinding in COVID-19 vaccine trials: recommendations of a WHO Expert Working Group. *Nature Medicine* 2021; 16 March 2021. <https://doi.org/10.1038/s41591-021-01299-5>.
109. * Singh JA, Bandewar SS, Palmero A and Bhan A. Acquiescence and submission to COVID-19 vaccination: ethics considerations. *Wellcome Open Research* 2021, 6:91. <https://doi.org/10.12688/wellcomeopenres.16745.1>
110. Adams R, Adeleke F, Anderson D, Bawa A, Branson N, Christoffels A, de Vries J, Etheredge H, Flack-Davison E, Gaffley M, Marks M, Mdhului M, Mahomed S, Molefe M, Muthivhi T, Ncube C, Olckers A, Papathanasopoulos M, Pillay J, Schonwetter T, Singh JA, Swanepoel C, Ramsay R. POPIA Code of Conduct for Research. *South African Journal of Science* 2021;117; 5/6. DOI: <https://doi.org/10.17159/sajs.2021/10933>
111. Wolff, J, Atuire C, Bhan A, Emanuel E, Faden R, Ghimire P, Greco D, Ho CWL, Kochhar S, Moon S, Schaefer OG, Shamsi-Gooshki E, Singh JA, Smith MJ, Thomé B, Touré A, Upshur R. Ethical and policy considerations for COVID-19 vaccination modalities: delayed second dose, fractional dose, mixed vaccines. *BMJ Global Health* 2021;6:e005912. doi:10.1136/bmjgh-2021-005912.
112. *Singh JA. COVID-19 vaccines: How macro-level factors can vitiate autonomy at the individual level. *Verfassungsblog: On Matters Constitutional* 2021: May: 1-9. DOI:10.17176/20210510-181550-0. https://intr2dok.vifa-recht.de/receive/mir_mods_00010592
113. Popkas K, Naidoo S, Kumar P, and Singh JA. Vaccine hesitancy: The role of the medical fraternity in debunking vaccine myths. *SAMA Insider* June 2021: 8-9. <http://www.samainsider.org.za/index.php/SAMAInsider/article/viewFile/116/89>
114. * Singh JA. Why the Global South is integral to the development of next-generation COVID-19 vaccines and antibody therapeutics. *University of Toronto Medical Journal* 2021; 98(3): 12-16. <https://utmj.org/index.php/UTMJ/article/view/1508/1322>
115. Krause PR, Fleming TR, Longini IM, Peto R, Briand S, Heymann DL, Beral V, Snape MD, Rees H, Ropero AM, Balicer RD, Cramer JP, Muñoz-Fontela C Gruber M, Sa Gaspar R, Singh JA, Subbarao K, Van Kerkhove MD, Swaminathan S, Ryan MJ, Henao-Restrepo A. SARS-CoV-2 variants and vaccines. *New England Journal of Medicine* 2021; June 23, 2021 DOI: 10.1056/NEJMSr2105280. <https://www.nejm.org/doi/full/10.1056/NEJMSr2105280>
116. Ravinetto R, Caillet C, Zaman MH, Singh JA, et al. Preprints in times of COVID19: the time is ripe for agreeing on terminology and good practices. *BMC Med Ethics* 2021; 22; 106. <https://doi.org/10.1186/s12910-021-00667-7>.
117. Moon S, Armstrong J, Hutler B, Upshur R, Katz R, Atuire C, Bhan A, Emanuel E, Faden R, Ghimire P, Greco D, Ho CW, Kochhar S, Schaefer GO, Shamsi-Gooshki E, Singh JA, Smith MJ, Wolff J. Governing the Access to COVID-19 Tools Accelerator: towards greater participation, transparency, and accountability. *Lancet*. 2021 Dec 10:S0140-6736(21)02344-8. doi: 10.1016/S0140-6736(21)02344-8. Epub ahead of print. PMID: 34902308.
118. Lyerly AD, Beigi R, Bekker LG, Chi BH, Cohn SE, Diallo DD, Eron J, Faden R, Jaffe E, Kashuba A, Kasule M, Krubiner C, Little M, Mfustso-Bengo J, Mofenson L, Mwapasa V, Mworeko L, Myer L, Penazzato M, Rid A, Shapiro R, Singh JA, Sullivan K, Vicari M, Wambui J, White A, Wickremsinhe M, Wolf L. Ending the evidence gap for pregnancy, HIV and co-infections: ethics guidance from the PHASES project. *J Int AIDS Soc*. 2021 Dec;24(12):e25846. doi: 10.1002/jia2.25846. PMID: 34910846.

2022

119. * Singh JA, Kochhar S, Wolff J, et al. WHO guidance on COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: Ethical considerations, *Vaccine* 2022; 14; 2140-2149. <https://doi.org/10.1016/j.vaccine.2022.02.038>.

120. * Singh JA. Seismic surveys: what constitutes meaningful consultation? *Quest: Science for South Africa* 2022; 18(1). <http://hdl.handle.net/20.500.11911/234>.

121. * Singh JA, Le Roux A, Naidoo S. Marine seismic surveys for hydrocarbon exploration: What's at stake? *S Afr J Sci.* 2022;118(3/4), Art. #13420. <https://doi.org/10.17159/sajs.2022/13420>.

122. * Singh JA, Moodley D, Little M, Luna F, Littler K, Kumarasamy N. The ethics of exclusion: why pregnant and lactating women must be front and centre of HIV research. *Journal of the International AIDS Society* 2022; 25(S2):e25926. <http://onlinelibrary.wiley.com/doi/10.1002/jia2.25926/full><https://doi.org/10.1002/jia2.25926>.

123. Ravinetto R and Singh JA. Responsible dissemination of health and medical research: some guidance points. *BMJ Evidence Based Medicine* Epub ahead of print: [1 Sep 2022]. doi:10.1136/bmjebm-2022-111967. <https://ebm.bmj.com/content/ebmed/early/2022/09/01/bmjebm-2022-111967.full.pdf>

124. Brand D, Singh JA, Nienaber McKay AG, Cengiz N, Moodley K. Data sharing governance in sub-Saharan Africa during public health emergencies: Gaps and guidance. *S Afr J Sci.* 2022;118(11/12), Art. #13892. <https://doi.org/10.17159/sajs.2022/13892>.

125. Kohler J, Singh JA, Stuart R, Samuelson J, Reis AA. Ethical implications of economic compensation for voluntary medical male circumcision for HIV prevention and epidemic control. *PLOS Glob Public Health* 2022; 2(12): e0001361. <https://doi.org/10.1371/journal.pgph.000136>.

2023

126. Mandima P, et al (Singh JA, as a member of the IMPAACT P1078 T. B. APPRISE study team). Prevalence of neurotoxicity symptoms among postpartum women on isoniazid preventive therapy and efavirenz-based treatment for HIV: an exploratory objective of the IMPAACT P1078 randomized trial. *BMC Pregnancy and Childbirth* 2023: 23:34.

127. * Singh JA. Adaptive clinical trials in public health emergency contexts: ethics considerations. *Wellcome Open Research* Wellcome Open Research 2023, 8:130 <https://doi.org/10.12688/wellcomeopenres.19057.1>.

128. * Singh JA. Governance of adaptive platform trials. *Wellcome Open Research* 2023, 8:141. <https://doi.org/10.12688/wellcomeopenres.19058.1>.

129. Sugarman J, Wenner DM, Rid A Henry LM, Luna F, Klitzman R, MacQueen KM, Rennie S, Singh JA, Gostin LO. Post-Dobbs research with people who can become pregnant. *Science* 2023; doi.org/10.1126/science.adh3104.

130. Littler K, Sheather J, Singh J, Wright K. Why climate change health policy needs ethics to achieve health equity and climate justice—a call to action. *BMJ.* 2023 Jun 20;381:1368. doi: 10.1136/bmj.p1368.

131. Wright K, Ali J, Davies A, Glasziou P, Gobat N, Kuchenmüller T, Littler K, Modlin C, Pascoe L, Reis A, Singh JA. Ethical priorities for international collaborative adaptive platform trials for public health emergencies. *BMJ Glob Health* 2023;8:e012930. doi:10.1136/bmjgh-2023-012930. <https://gh.bmj.com/content/bmjgh/8/7/e012930.full.pdf>.

132. Sheather J, Littler K, Singh JA and Wright K. Ethics, climate change and health – a landscape review. *Wellcome Open Res* 2023, 8:343. <https://doi.org/10.12688/wellcomeopenres.19490.1>.

Chapters and books

Published Chapters

1999

1. McQuoid-Mason DJ and Singh JA. Medicine, Dentistry, Pharmacy and other Health Professions. In: WA Joubert (ed) *The Law of South Africa*. Vol. 17 R. Durban: Butterworths: 1999: 129-230.

2001

2. * Singh JA and Ngwena C. Bioethics. In: Dada MA, McQuoid-Mason DJ (eds.) *Introduction to Medico-Legal Practice*. Durban: Butterworths: 2001: 33-52.

2002

3. * Singh JA. E-Commerce in South Africa – A Consideration of Selective Issues. In: Fitzgerald A. and Moens A. (eds.) *International E-Commerce Regulation*. Brisbane, Australia: Thomson Lawbook Co: 2002: 341-353.

4. McQuoid-Mason DJ and Singh JA. Veterinary Practice. In: Joubert W.A. (ed) *The Law of South Africa*. Vol. 30. Durban: Butterworths: 2002: 147-175.

2003

5. * Singh JA. Electronic Payment Systems in South Africa – Current State of Play. In: Mendez-Vilas A, González J.A.M, Bote V.G and Alonso F.Z (eds.) *Techno-Legal Aspects of Information Society and New Economy: An Overview*. Vol. 1. Badajoz, Spain: Formatex Publishers: 2003: 116-119.

2005

6. * Singh JA. AIDS: the impact on ethics. In: Abdool Karim SS and Abdool Karim Q. *HIV/AIDS in South Africa*. Cape Town: Cambridge University Press: 2005: 346-366.

7. * Singh JA. Stem cell research in South Africa. In: Bender W. Hauskeller C. Manzei A. (ed.) *Crossing Borders. Cultural, Religious and Political Differences Concerning Stem Cell Research*. Munster, Germany: Agenda Verlag: 2005: 225-237.

8. Gray A, Govender M, Gengiah T & Singh JA. Health legislation: 2004/5. In: *South African Health Review 2004/5*. Durban: Health Systems Trust: 2005: 16-30.

2007

9. * Singh JA. Could investigators foresee the outcome of the Tigray Malaria trial? In: Lavery JV, Wahl E, Grady C & Emanuel EJ (eds.) *Ethical issues in International Biomedical Research*. New York: Oxford University Press: 2007: 126-130.

10. * Singh JA. Epidemiology: ethics, advocacy and human rights. In: Joubert G and Ehrlich (exec eds.) *Epidemiology: a research manual for South Africa*. Cape Town: Oxford University Press: 2007: 30-38.

2008

11. * Singh JA. Physicians and torture. In Singer PA and Viens A (eds.). *The Cambridge Textbook on Bioethics*. London: Cambridge University Press: 2008: 350-358.

12. * Singh JA. Humanitarian work and infection control: legal, ethical, human rights, and social considerations. In Biquet J-M (ed.). *Humanitarian Stakes No. 1: MSF Switzerland's Review on Humanitarian Stakes and Practices*. Geneva: MSF: 2008: 12-22.

2010

13. * Singh J.A. AIDS: the impact on ethics. In: Abdool Karim SS and Abdool Karim Q. *HIV/AIDS in South Africa*. 2nd ed. Cape Town: Cambridge University Press: 2010: 393-416.

2011

14. * Singh JA. Law and the Health Professional in South Africa. In: Moodley K (ed) *Medical Ethics, Law and Human Rights: a South African Perspective*. Second edition. Van Schaik Press: 2011: 109-142.

15. * Singh JA. Teenage Sexuality, Ethics, and Law: *Kids*. In: Colt H, Quadrelli S, and Friedman L (eds). *The Picture of Health: Medical Ethics and the Movies*. Oxford University Press: 2011: 59-62.

16. * Singh JA. Humanitaire, médecine et éthique (Humanitarian medicine and ethics). In Abu-Sada C (ed) *Dans l'oeil des autres. Perception de l'action humanitaire et de MSF (In the eye of others. Perception of humanitarian action and MSF)*. Geneva: Médecins Sans Frontières: 2011: 157-163.

2012

17. Singh JA. Global health governance and ethics. In: Upshur REG and Pinto A (eds). *An Introduction to Global Health Ethics*. Routledge: 2012: 58-72.

18. Singh JA. Humanitarian medicine and ethics. In: Abu-Sada C (ed). *In the eye of others. Perception of humanitarian action and MSF*. Geneva: Médecins Sans Frontières: 2012: 164-172.

19. Singh JA. *Humanitarian medicine and ethics In the eye of others. Perception of humanitarian action and MSF*. Geneva: Médecins Sans Frontières: 2012 (Arabic translation).

2014

20. Forman L and Singh JA. *The role of rights and litigation in assuring more equitable access to health care in South Africa*. In: Flood CM and Gross A (eds.) *The Right to Health at the Public/Private Divide. A Global Comparative Study*. London: Cambridge University Press: 2014: 288-318.

21. Singh JA. Ethics, advocacy and human rights. In: Joubert G and Ehrlich R (eds.) *Epidemiology: a research manual for South Africa*. 3rd ed. Cape Town: Oxford University Press: 2014: 33-41.

2015

22. Singh JA. Ethical and Legal Responsibilities of Prescribers. In: *South African National Blood Services Transfusion Medicine Short Course Manual*: SANBS: 2015: 47-49.

2016

23. Forman L and Singh JA. The role of rights and litigation in assuring more equitable access to health care in South Africa. In: Kepe T, Levin M, and von Lieres B (eds). *Domains of Freedom. Justice, citizenship and social change in South Africa*. UCT Press: 2016: 167-198.

2017

24. Singh JA. Ethical and legal considerations for realising post-trial access of novel experimental interventions: lessons from the CAPRISA 004 trial. In: Abdool-Karim SS, Baxter C, and Abdool-Karim Q, (eds). *CAPRISA's clinical trials to improve HIV prevention and treatment*. Springer 2017: 191-200.

25. Singh JA. Law and the Health Professional in South Africa. In: Moodley K (ed) *Medical Ethics, Law and Human Rights: a South African Perspective*. 2nd ed. Van Schaik Press 2017: 129-165.

2021

26. Singh JA and Moodley K. Research ethics. In: Joubert G and Myer L. (exec eds.) *Epidemiology: a research manual for South Africa*. 3rd ed. Cape Town: Oxford University Press: 2021: 39-47.

2022

27. Singh JA. COVID-19 Vaccines and Global Governance: How Structural Factors Dictate Procurement and Vitiolate Patient Autonomy. In: Grogan J and Donald A (eds). *Routledge Handbook on Law and the COVID-19 Pandemic*. Routledge: 2022: 18-30.

28. Soodyal H and Singh JA. How to treat private and sensitive medical and genetic data. In: Jones C, Kruger M, van den Heever J, & van Niekerk A (eds.). *Challenges in Medical Ethics: the South African context*. Stellenbosch: African Sun Media: 2022: 217-239.

2023

29. Singh JA. Law and the Health Professional in South Africa. In: Moodley K (ed) *Bioethics, medical law, and human rights*. 3rd ed. Van Schaik Press. 2023.

Technical reports / guidance documents / policy briefs

2004

1. * Singh JA and Strode AE. A Comparative International Analysis of Health Systems and Research Regulation Schemes: An Analysis of South Africa's Health Systems and Research Regulation Schemes 2004: 1-50. Report for Genome Canada.

2005

2. * Singh JA (co-authors: Abdool-Karim A, Baxter C, and Mellors S) Creating effective partnerships for clinical trials: Report on the UNAIDS Southern and Eastern African Regional Consultation workshop: Durban, South Africa, 24 – 26 April 2005. Report for UNAIDS (as a UNAIDS Regional Rapporteur).

3. * Singh JA. Research Ethics Review Structures: International Comparisons: South Africa. In: Trudo Lemmens and Tom Archibald (eds). The Regulation and Organization of Research Ethics Review Report of a Comparative International Workshop held at the Faculty of Law, University of Toronto, June 16-18, 2005. Toronto, Canada: Brown Book Company Ltd., 2006.
<https://www.law.utoronto.ca/documents/Lemmens/workshop%20booklet%20pub%20Feb%202007.pdf>.

2009

4. * Singh JA. Public health legislation in South Africa: constitutionality, obsolescence, and redundancy. Report for the South African Law Reform Commission (as a member of the SALRC Committee on Health Law). January 2009.

5. * Singh JA (co-authors Larry Gostin and Oscar Cabrera). Ethical, human rights, and legal issues in managing drug-resistant TB. Report for the World Health Organisation (as members of the WHO Task Force on Addressing Ethical Issues in TB Control Programmes). February 2009. Incorporated into: WHO. Guidance on ethics of tuberculosis prevention, care and control. 2010.
http://apps.who.int/iris/bitstream/handle/10665/44452/9789241500531_eng.pdf;jsessionid=AC9202E7B9C4C665D353CD2166ABE743?sequence=1.

2013

6. * Singh JA (human rights and law contributor: Programmatic Guideline Development Group). World Health Organisation (2013) Consolidated Guidelines on the use of antiretrovirals for the treatment and prevention of HIV infection: Recommendations for a public health approach. Available at WHO website:
http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf

7. * Singh JA (author: page 12-13) World Health Organisation (2013) Guidance for HIV Testing and Counselling (HTC) for adolescents and treatment and care for adolescents living with HIV: Recommendations for a public health approach. Available at WHO website:
http://apps.who.int/iris/bitstream/10665/94334/1/9789241506168_eng.pdf

8. Fox K, Ferguson J, Ajose W, Singh JA, Marum E, and Baggaley R. Adolescent consent to testing: a review of current policies and issues in sub-Saharan Africa. In: HIV and Adolescents: Guidance for HIV Testing and Counselling and Care for Adolescents Living with HIV: Recommendations for a Public Health Approach and Considerations for Policy-Makers and Managers. Geneva: World Health Organization; 2013. ANNEX 15. Available at WHO website:
<http://www.ncbi.nlm.nih.gov/books/NBK217954/>

2014

9. Singh JA (reviewer/contributor). World Health Organisation (2014). Considerations regarding consent in vaccinating children and adolescents between 6 and 17 years old. 2014. Available at WHO website: <https://apps.who.int/iris/handle/10665/259418>

2016

10. Singh JA et al (2016). In: International AIDS Society (IAS). Full recommendations: Towards an HIV Cure. Available at IAS website:
https://www.iasociety.org/web/webcontent/file/hiv_cure_full_recommendations_2016.pdf.

2017

11. * Singh JA and Jogee F. Age of Consent: Ethical, Cultural, and Social Review. South Africa Country Report. In: UNICEF (United Nations Children's Fund), SAT (Sexual and Reproductive Rights Africa Trust), et al (2017). Age of Consent: Legal, Ethical, Cultural, and Social Review. South Africa Country Report. Published by SAT. Available at SAT website: <http://www.satregional.org/wp-content/uploads/2018/05/Age-of-consent-South-Africa.pdf>.

12. * Singh JA and Jogee F. Age of Consent: Ethical, Cultural, and Social Review. Nigeria Country Report. In: UNICEF (United Nations Children's Fund), SAT (Sexual and Reproductive Rights Africa Trust), et al (2017). Age of Consent: Legal, Ethical, Cultural, and Social Review. Nigeria Country Report. Published by SAT. Available at SAT website: <http://www.satregional.org/wp-content/uploads/2018/05/Age-of-consent-Nigeria.pdf>.

13. * Singh JA and Jogee F. Age of Consent: Ethical, Cultural, and Social Review. Ukraine Country Report. In: United Nations Children's Fund, UNICEF), SAT (Sexual and Reproductive Rights Africa Trust), et al (2017). Age of Consent: Legal, Ethical, Cultural, and Social Review. Ukraine Country Report. Published by SAT. Available at SAT website: <http://www.satregional.org/wp-content/uploads/2018/05/Age-of-consent-Ukraine.pdf>.

14. * Singh JA and Jogee F. Age of Consent: Ethical, Cultural, and Social Review. United Kingdom Country Report. In: UNICEF (United Nations Children's Fund), SAT (Sexual and Reproductive Rights Africa Trust), et al (2017). Age of Consent: Legal, Ethical, Cultural, and Social Review. United Kingdom Country Report. Published by SAT. Available at SAT website: <http://www.satregional.org/wp-content/uploads/2018/05/Age-of-consent-United-Kingdom.pdf>.

15. * Singh JA and Jogee F. Age of Consent: Ethical, Cultural, and Social Review. India Report. In: UNICEF (United Nations Children's Fund), SAT (Sexual and Reproductive Rights Africa Trust), et al (2017). Age of Consent: Legal, Ethical, Cultural, and Social Review. India Country Report. Published by SAT. Available at SAT website: <http://www.satregional.org/wp-content/uploads/2018/05/Age-of-consent-India.pdf>.

16. * Singh JA and Jogee F. Age of Consent: Ethical, Cultural, and Social Review. Indonesia Country Report. In: UNICEF (United Nations Children's Fund), SAT (Sexual and Reproductive Rights Africa Trust), et al (2017). Age of Consent: Legal, Ethical, Cultural, and Social Review. Indonesia Country Report. Published by SAT. Available at SAT website: <http://www.satregional.org/wp-content/uploads/2018/05/Age-of-consent-Indonesia.pdf>.

17. * Singh JA and Chereka S. Age of Consent: Ethical, Cultural, and Social Review. Brazil Country Report. In: UNICEF (United Nations Children's Fund), SAT (Sexual and Reproductive Rights Africa Trust), et al (2017). Age of Consent: Legal, Ethical, Cultural, and Social Review. Brazil Country Report. Published by SAT. Available at SAT website: <http://www.satregional.org/wp-content/uploads/2018/05/Age-of-consent-Brazil.pdf>.

18. * Singh JA and Chereka S. Age of Consent: Ethical, Cultural, and Social Review. Jamaica Country Report. In: UNICEF (United Nations Children's Fund), SAT (Sexual and Reproductive Rights Africa Trust), et al (2017). Age of Consent: Legal, Ethical, Cultural, and Social Review. Jamaica Country Report. Published by SAT. Available at SAT website: <http://www.satregional.org/wp-content/uploads/2018/05/Age-of-consent-Jamaica.pdf>.

19. * Singh JA and Chereka S. Age of Consent: Ethical, Cultural, and Social Review. Philippines Country Report. In: UNICEF (United Nations Children's Fund), SAT (Sexual and Reproductive Rights Africa Trust), et al (2017). Age of Consent: Legal, Ethical, Cultural, and Social Review. Philippines Country Report. Published by SAT. Available at SAT website: <http://www.satregional.org/wp-content/uploads/2018/05/Age-of-consent-Philippines.pdf>.

20. * Singh JA and Chereka S. Age of Consent: Ethical, Cultural, and Social Review. Thailand Country Report. In: UNICEF (United Nations Children's Fund), SAT (Sexual and Reproductive Rights Africa Trust), et al (2017). Age of Consent: Legal, Ethical, Cultural, and Social Review. Thailand Country Report. Published by SAT. Available at SAT website: <http://www.satregional.org/wp-content/uploads/2018/05/Age-of-consent-Thailand.pdf>.

2018

21. Singh JA (author / contributor: various parts pertaining to public health legislation). South African Law Reform Commission. Project 25: Report on Statutory Law Revision: Legislation administered by Department of Health. 30 June 2018. Available: http://www.justice.gov.za/salrc/reports/r_prj25_DOH-Report-Feb2019.pdf.

22. * Singh JA (sole author). World Health Organisation (2018). Guidance on ethical considerations in planning and reviewing research studies on sexual and reproductive health in adolescents. Available: <http://apps.who.int/iris/bitstream/handle/10665/273792/9789241508414-eng.pdf> or <http://www.who.int/reproductivehealth/publications/adolescence/ethical-considerations-srh-research-in-adolescents/en/>.

2019

23. Singh JA (contributor: pg 73-82) World Health Organisation. Ethics in implementation research. Facilitator's guide. 2019. Available: <https://apps.who.int/iris/bitstream/handle/10665/325608/9789241515375-eng.pdf>

2020

24. World Health Organisation Expert Group on Ethics & Governance of Artificial Intelligence. Ethical considerations to guide the use of digital proximity tracking technologies for COVID-19 contact tracing. Interim guidance. 28 May 2020. https://apps.who.int/iris/bitstream/handle/10665/332200/WHO-2019-nCoV-Ethics_Contact_tracing_apps-2020.1-eng.pdf.

25. Singh JA (member of the Guideline Development Group). World Health Organisation. Preventing HIV through safe voluntary medical male circumcision for adolescent boys and men in generalized HIV epidemics: recommendations and key considerations. <https://www.who.int/publications/i/item/preventing-hiv-through-safe-voluntary-medical-male-circumcision-for-adolescent-boys-and-men-in-generalized-hiv-epidemics-guidelines>

26. Singh JA (co-author with Coleman C). Ethical issues in gene drive vector borne disease research. In: World Health Organisation. Ethics & Vector-borne Diseases Guidance 2020. <https://apps.who.int/iris/bitstream/handle/10665/336075/9789240012738-eng.pdf>.

27. Singh JA (drafter on behalf of the World Health Organisation Access to COVID-19 Tools Accelerator Ethics and Governance Working Group). Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding. Policy brief. 18 December 2020. https://apps.who.int/iris/bitstream/handle/10665/337940/WHO-2019-nCoV-Policy_Brief-EUD_placebo-controlled_vaccine_trials-2020.1-eng.pdf?sequence=1&isAllowed=y.

2021

28. Singh JA. (drafter on behalf of the World Health Organisation Access to COVID-19 Tools Accelerator Ethics and Governance Working Group). COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: ethical considerations. Policy brief. 26 November 2021. <https://apps.who.int/iris/handle/10665/349693>.

Public Interest Advisories

2021

1. Scientific Advisory Group on Emergencies (SAGE) Advisory on the outbreak of foot-and-mouth disease in KwaZulu-Natal in June-July 2021: mitigating a potential emergency. SAGE Sub-committee on Foot and Mouth Disease (Marufu MC, Karama M, Mwale-Manjoro M, Mapiye C, Singh JA, Naidoo S, Le Roux A). 12 July 2021.

<https://www.assaf.org.za/files/2021/1/SAGE%20advisory%20FMD%20-%2012%20July%202021%20revised.pdf>.

2. Scientific Advisory Group on Emergencies (SAGE) Situational and Strategic Advisory on Social and Political Instability in South Africa: July 2021. (Singh JA, McQuoid Mason DJ, Gray G, Pillay B, Manjoro M, Aremu A, Pokpas K, Naidoo S, Kumar P, Le Roux A, Pillay A). 14 July 2021.

<https://www.assaf.org.za/files/2021/1%20SAGE%20Situational%20and%20Strategic%20Advisory%20on%20Social%20and%20Political%20Instability%20revised%20-%2014%20July%202021.pdf>.

3. Scientific Advisory Group on Emergencies (SAGE) Situational Analysis and Strategic Advisory on Farming and Food Security In South Africa in the Aftermath of Widespread Public Violence and Looting in Kwazulu-Natal and Gauteng between 10-14 July 2021. SAGE Sub-Committee on Food Security (Tatsvarei S, Mwale-Manjoro M, Mapiye C, Marufu MC, Singh JA, Letty BA, Naidoo S, Wright C, Aremu A). 30 July 2021; revised 30 August 2021.

<https://www.assaf.org.za/files/2021/1%20SAGE%20Food%20Security%20Advisory%20revised%20-%2030%20Aug%202021.pdf>.

2022

4. Scientific Advisory Group on Emergencies (SAGE) Advisory on the use of deep-sea seismic surveys to explore for oil and gas deposits in South African waters - 10 January 2022. SAGE Sub-committee on Marine Ecology and Risk Mitigation (le Roux A, Singh JA, Ansorge I, Bornman T, Elwen S, Gammage L, Naidoo S, Rajkaran A, Vrancken P, Kumar P, Manjoro M). 10 January 2022.

<https://www.assaf.org.za/files/2022/SAGE/SAGE%20Advisory%20on%20Shell%20Seismic%20Survey.pdf>

5. Scientific Advisory Group on Emergencies (SAGE) Sub-committee on Marine Ecology and Risk Mitigation (represented by Singh JA, le Roux A, Naidoo S). Response to EnerGeo Alliance (EA) and African Energy Chamber (AEC) - Advisory on the use of deep-sea seismic surveys to explore for oil and gas deposits in South African waters - 1 February 2022.

<https://www.assaf.org.za/files/2022/SAGE/Response%20to%20EnerGeo%20and%20AEC%20concordance%20-%201%20Feb%202022%20-%20final2.pdf>.

2023

6. Scientific Advisory Group on Emergencies (SAGE) Sub-committee on the Environmental and Heritage Implications of South Africa's Makhado-Musina Special Economic Zone (le Roux A, Taylor PJ, Foord S, Liebenberg L, Rosmarin J, Mugwedi L, Pokpas K, Naidoo S, Singh JA). 18 January 2023. <https://www.assaf.org.za/wp-content/uploads/2023/01/SAGE-Scientific-Advisory-on-the-environmental-and-heritage-implications-of-South-Africa-MMSEC1-18-January-2023.pdf>.

7. SAGE Sub-committee on Water Security and Water Quality. Strategic Advisory on Wastewater Management in South Africa. (Singh JA, Pokpas K, Naidoo S, Otomo PV, Kanyerere T, Petrik L, Ikumi D, Mazvimavi D, Clarke S, Jovanovic N, Nkambule S, Street R, Manjoro M, Sheridan C, and Le Roux A). 06 June 2023. <https://www.assaf.org.za/2023/06/07/strategic-advisory-on-wastewater-management-in-south-africa/>.

Online publications: blogs, letters

2003

1. * Singh J.A and Depellegrin T. Re: Islamic ethics and war. 13 April 2020. <http://bmj.com/cgi/eletters/326/7393/774#31193>.
2. * Singh J.A and Depellegrin T. Re: Images of war - the other side. 13 April 2003. <http://bmj.com/cgi/eletters/326/7393/774#31193>.
3. * Singh J.A and Depellegrin T. Re: Images of war must be shown. 13 April 2003. <http://bmj.com/cgi/eletters/326/7393/774#31193>.
4. * Singh J.A and Depellegrin T. Re: Shallow Criticism. 13 April 2003. <http://bmj.com/cgi/eletters/326/7393/774#31193>.

2020

5. * Singh JA. COVID-19: putting the poor and vulnerable on the radar. WHO Ethics, 9 April 2020. [commentary]. <https://epidemicethics.tghn.org/community/blogs/post/258785/2020/04/covid-19-putting-poor-and-vulnerable-radar/>
6. Ravinetto R, Guerin PJ, Zaman MH, Caillet C, Singh JA, Newton PN. Waste in covid-19 research and the use of pre-prints. 18 May 2020. <https://www.bmj.com/content/369/bmj.m1847/rapid-responses>.

Popular press publications

2003

1. * Singh J.A. Weapons of Mass Destruction. *National Geographic* 2003; March: vi [Forum].
2. Abdool-Karim SS and Singh JA. "What's all the noise about? 'Dr Death' says what he did for the apartheid state was 'same as developing new Aids drug'." *Sunday Times*: 21 January 2016 [Letter to the editor] <http://www.caprisa.org/News/Read/30096>.
3. * Singh JA and Jogee F. The shocking truth. Social and cultural factors drive HIV infection in South African adolescents. *Sunday Tribune*: 24 July 2016 [Commentary]. <https://www.pressreader.com/south-africa/sunday-tribune/20160724/281943132240579>
4. * Singh JA. COVID-19: All South Africans need to stand together in solidarity. Why the President's declaration of a lockdown is ethical and deserves our support. 25 March 2020 [commentary].
Mercury: <https://www.gate5.co.za/read/99839/qv/84733024/147799682/17410/p>;
Cape Times: <https://www.gate5.co.za/read/99839/qv/84732076/147799163/17410/p>;
Pretoria News: <https://www.gate5.co.za/read/99839/qv/84732250/147799293/17410/j>
5. * Singh JA. Covid-19: KZN Premier needs to come clean about stance on self-isolation. April 29, 2020. <https://www.iol.co.za/news/opinion/covid-19-kzn-premier-needs-to-come-clean-about-stance-onself-isolation-47339583>.
6. Kruger M, Dhai A, Singh JA, Mokhachane M, Gray G, Mdhuli M. Why all children older than 12 need to get the Covid-19 jab. *Daily Maverick*. 5 December 2021. https://www.dailymaverick.co.za/article/2021-12-05-why-all-children-older-than-12-need-to-get-the-covid-19-jab/?utm_medium=email&utm_campaign=First%20Thing%20Monday%206%20December%202021&utm_c

[ontent=First%20Thing%20Monday%206%20December%202021+CID_223d04e8efa36802bd4bce831dc5b1da&utm_source=TouchBasePro&utm_term=Why%20all%20children%20older%20than%2012%20need%20to%20get%20the%20Covid-19%20jab](https://www.touchbasepro.com/ontent=First%20Thing%20Monday%206%20December%202021+CID_223d04e8efa36802bd4bce831dc5b1da&utm_source=TouchBasePro&utm_term=Why%20all%20children%20older%20than%2012%20need%20to%20get%20the%20Covid-19%20jab)

Abstracts, minor contributions to books, collected conference proceedings

1999

1. * Singh J.A. Scenarios. In: McQuoid Mason D.J and Dada M.A (eds.). *Guide to Forensic Medicine and Medical Law*. Independent Medico-legal Unit, Durban: 1999: 93-94.

2000

2. * Singh J.A. Teaching Bioethics from an African Perspective. *Book of Proceedings of the 2000 Commonwealth Legal Education Association Conference*. April 2000: 1-15 (loose-leaf collection).

3. * Singh J.A. Informed Consent and Testing for HIV/AIDS – Legal and Ethical Issues: Scenarios. *Book of Proceedings of the First South African Conference on Post-Exposure Prophylaxis and Needlestick Injuries*. June 2000: 24–25.

4. * Singh J.A. South Africa's Chemical and Biological Warfare Programme and its Impact of Science, Morality and Humanity. *Book of Proceedings of the 2000 World Congress on Medical Law*. August 2000: 1067.

5. * Singh J.A. After Birth where there is a Sub-optimal Outcome for the Baby. *Book of Proceedings of the 2000 National Gynecology and Obstetrics Conference*. October 2000: 7.

2004

6. * Singh JA. Are *all* HIV+ patients legally entitled to receive ARV therapy? *24th Medicine Update Symposium Book of Proceedings*, September 2004: 63-69.

2011

7. * Singh JA. Summary of recommended steps to follow when testing a person for HIV. In: Moodley K (ed) *Medical Ethics, Law and Human Rights: a South African Perspective*. Van Schaik Press: 2011: 238.

Selected papers at conferences, seminars, capacity building initiatives

1999

1. Singh JA. The Legal Aspects of Human Cloning. Society of Law Teachers of Southern African Conference, Bloemfontein, South Africa, January 1999.

2. Singh JA (co-author: Dada MA). The Medico-legal Aspects of Molecular Medicine (invited speaker). The International Academy of Pathologists Conference, Durban, South Africa, September 1999.

2000

3. Singh JA. Teaching Bioethics from an African Perspective. The Commonwealth Legal Education Association Conference, Adelaide, Australia, April 2000.

4. Singh JA. Informed Consent and Testing for HIV / AIDS - Legal and Ethical Issues (invited speaker). The First South African Conference on HIV Post-Exposure Prophylaxis and Needlestick Injuries, Durban, South Africa, June 2000.

5. Singh JA. The Impact of Chemical and Biological Warfare on Public Health in Southern Africa. Society of Law Teachers of Southern Africa Conference, Durban, South Africa, July 2000.

6. Singh JA. Euthanasia and End of Life Decisions in Critical Care Wards (invited speaker). Combined Congress of the Critical Care Society of Southern Africa and the South African Pulmonology Society (Incorporating The Society of Cardiothoracic Surgeons), Durban, South Africa, July 2000.

7. Singh JA. South Africa's Chemical and Biological Warfare Programme and its Impact on Science, Morality and Humanity. The World Congress on Medical Law, Helsinki, Finland, August, 2000.

8. Singh JA. The Legal and Ethical Status of Assisted Reproductive Techniques in South Africa (invited speaker). National Gynecology and Obstetrics Conference, Durban, South Africa, October 2000.

9. Singh JA. The Issue of Litigation After Birth where there is a Sub-optimum Outcome for the Baby (invited speaker). National Gynecology and Obstetrics Conference, Durban, South Africa, October 2000.

2001

10. Singh JA. The Human Genome Project and Eugenics: Lessons from South Africa. Second International AmFITan Conference on Developmental Ethics, Tampa, USA, February 2001.

11. Singh JA. Project Coast: South Africa's Biogenocide Program, The Scientific Community and the Role of the United States (invited speaker). Biology Seminar, Washington University in St Louis, USA, February 2001.

12. Singh JA. Globalization and the Spread of CBW Proliferation. Commonwealth Legal Education Association Conference, Colombo, Sri Lanka, December 2001.

13. Singh JA. Information Technology, Globalization and Africanization. Commonwealth Legal Education Association Conference, Colombo, Sri Lanka, December 2001.

2002

14. Singh JA. The Ethical and Legal Implications of Cosmetic Dermatology (invited speaker). South African National Dermatology Conference, Durban, South Africa, April 2002.

15. Singh JA. The Ethical and Legal Implications of Treating HIV Positive Patients for Dermatological Purposes (invited speaker). South African National Dermatology Conference, Durban, South Africa, April 2002.

2003

16. Singh JA. Why there should be no compulsory HIV testing of patients before surgery (invited speaker: debate) International Congress of Surgery, Toronto, Canada, May 2003 [cancelled because of SARS].

17. Singh JA. Ethical issues in AIDS therapy (invited speaker). 1st South African National AIDS Conference, Durban, South Africa, August 2003.

18. Singh JA. How national disregard for International Humanitarian Law can create dual loyalty conflicts of interests for military physicians (invited speaker). 5th Course on International Law of Armed Conflict organized by the International Committee of Military Medicine, Spiez, Switzerland, August 2003.

19. Singh JA. Challenges of gathering and using evidence in the developing world (invited speaker). American Bioethics and Humanities Association / Canadian Bioethics Society Conference, Montreal, Canada, October 2003.

2004

20. Singh JA. Ethical-legal regulation of research in South Africa: Implications for HIV vaccine trials (invited speaker). South African AIDS Vaccine Initiative (SAAVI) seminar, Karridene, South Africa, June 2004.

21. Singh JA. A summary of the standard of care debate (invited speaker). MRC/HIV Aids Network (HIVAN) AIDS forum, Durban, Pietermaritzburg, Mtunzini, South Africa, June 2004.

22. Singh JA. Legislative provisions in South Africa to protect research participants (invited speaker). Human Sciences Research Council (HSRC) Conference, Pretoria, South Africa, July 2004.

23. Singh JA. Ethical issues in HIV/AIDS research: standards of care in the post-HIV ARV rollout world (invited speaker). International Research Ethics Network of SA (IRENSA) seminar, Cape Town, South Africa, August 2004.

24. Singh J.A. Dual loyalty and constitutional implications of restrictive managed care practices (invited speaker). Managed Care Coalition Conference, Johannesburg, South Africa, August 2004.

25. Singh JA. Should disclosure of medical errors be made compulsory? (Invited speaker). 20th South African Thoracic Society Congress, Durban, South Africa, August 2004.

26. Singh JA. Are *all* HIV+ patients legally entitled to receive ARV therapy? (Invited speaker). 24th Medicine Update Symposium, Durban, South Africa, September 2004.

27. Singh JA. Dual use technology and bio-weapon proliferation: lessons from South Africa (invited speaker). US National Academies of Sciences workshop on Advancing Technologies and Strategies for Managing Dual Use Risk. Cuernavaca, Mexico, September 2004.

28. Singh JA and Govender M. Clinical practice and resource allocation: ethical dilemmas in a South African setting (Invited Speaker). Paediatrics Department Grand Rounds, Nelson R. Mandela School of Medicine, Durban, South Africa, September 2004.

29. Singh JA. Implications of the National Health Act, 61 of 2003, for service providers (Invited Speaker). Infection Control Society KZN Symposium, Albert Luthuli Hospital, Durban, South Africa, October 2004.
30. Singh JA. HIV / AIDS and Informed Consent – Legal and Ethical Considerations (Invited Speaker). Global Fund workshop on Occupational Health and Safety, Durban, South Africa, October 2004.
31. Singh JA. HIV / AIDS and Confidentiality - Legal and Ethical Considerations (Invited Speaker). Global Fund workshop on Occupational Health and Safety, Durban, South Africa, October 2004.
32. Singh JA. Ethics and HIV care. (Invited speaker). First Annual Provincial Summit on HIV and AIDS in the Workplace, Durban, South Africa, November 2004.
33. Singh JA. Medical malpractice and the implications of the National Health Act, 61 of 2003 (Invited Speaker), Addington Hospital Seminar, Durban, South Africa, November 2004.

2005

34. Singh JA (co-presenters: Gengiah T, Carrera H). The process of research ethics regulation (invited speakers). UNAIDS Southern and Eastern African Regional Consultation: Creating effective partnerships for clinical trials, Durban, South Africa, April 2005.
35. Singh JA. An overview of challenges and issues in the HIV prevention trial informed consent process (invited speaker). Population Council workshop on informed consent in HIV prevention trials, New York, USA, May 2005.
36. Singh JA. HIV/AIDS and confidentiality: duties of health workers and support staff (invited speaker). Addington Hospital Seminar, Durban, South Africa, May 2005).
37. Singh JA. Law and ethics for the pharmacist (invited speaker). Professional training seminar for pharmacists, Westville, Durban, South Africa, May 2005.
38. Singh JA. Ethical issues in the management of HIV (invited speaker). KZN Managed Care Coalition AGM and Conference, Durban, South Africa, May 2005.
39. Singh JA. Research ethics review and regulation in South Africa. Genome Canada conference on research ethics regulation (invited speaker), Toronto, Canada, June 2005.
40. Singh JA. Informed consent in South Africa. Addington Hospital Seminar, Durban, South Africa, June 2005.
41. Singh JA. International humanitarian law, clinical ethics guidelines, and the treatment of political detainees (invited speaker). Islamic Medical Association Conference, Durban, South Africa, July 2005.
42. Singh JA. Children's rights: problems, gaps and opportunities for law reform (invited speaker). HAVEG Children's Forum, Durban, South Africa, July 2005
43. Singh JA. HIV/AIDS: confidentiality and disclosure in respect of adult and pediatric patients (invited speaker). Addington Hospital Seminar, Durban, South Africa, July 2005.
44. Singh JA. Sterilizing the mentally incompetent in South Africa: legal and ethical considerations (invited speaker). Gynecology Association Seminar, Durban, South Africa, July 2005.

45. Singh JA. International Humanitarian Law and dual loyalty obligations (invited speaker). 7th Course on International Law of Armed Conflict organized by the International Committee of Military Medicine, Spiez, Switzerland, August 2005.
46. Singh JA. Ethics and HIV care in the workplace. Development of an HIV/AIDS Programme (invited speaker). KwaZulu-Natal Provincial Workshop, Durban, South Africa, September 2005.
47. Singh JA. Ethical issues in suicide prevention research: a critical analysis of a proposed suicide study in Durban (invited speaker). International Association of Suicide Prevention Conference, Durban, South Africa, September 2005.
48. Singh JA. Bio-security: Lessons from South Africa (invited speaker). The 1st Workshop on the Global Bargain for Bio-security and Health, Kampala, Uganda, September 2005.
49. Singh JA. The various grounds for disputes relating to HIV/AIDS in the workplace, namely, unfair dismissal, unfair labour practice; unfair discrimination, and their respective dispute resolution paths (invited speaker). Annual Seminar on HIV/AIDS and the workplace sponsored by the Global Fund for AIDS, TB and Malaria / CCMA / Durban Chamber of Commerce. Durban, South Africa, October 2005.
50. Singh JA. How questionable political, scientific and legal ideology can compromise the ethical practice of HIV/AIDS research: the case of South Africa (invited speaker). Global Research Ethics: Protecting participants across the world and across cultures. Seminar of the Association of Research Ethics Committees, London, UK, November 2005.
51. Singh JA. Complying with United Nations Security Council Resolution 1540: challenges it poses to developing countries (invited speaker). Workshop on Assisting States to Effectively Fulfill UNSCR 1540's Legal Requirements, New York City, USA, November 2005.

2006

52. Singh JA. Ethical issues in research involving public health, health systems, and health services: how the judiciary can impose minimum standards of ethics – the experience of South Africa (invited speaker). Seventh Global Forum for Bioethics in Research, Karachi, Pakistan, February 2006.
53. Singh JA. How the slow ARV rollout in public hospitals is impacting on standards of care in South Africa's HIV research environment (invited speaker). Transforming Public Hospitals in South Africa Conference, Johannesburg, South Africa, March 2006.
54. Singh JA. Ethical issues in physiotherapy practice (invited speaker). National Physiotherapy Forum, Durban, South Africa. May 2006.
55. Singh JA. Ethical issues in cluster randomized clinical trials (invited speaker). Aurum Institute for Health Research Seminar, Johannesburg, South Africa, June 2006.
56. Singh JA. Medical negligence and neo-natal wards (invited speaker). Empangeni Hospital Seminar, Empangeni, South Africa, May 2006.
57. Singh JA. Hospital ethics committees: composition, functions, and powers (invited speaker). Empangeni Hospital Seminar, Empangeni, South Africa, May 2006.
58. Singh JA. Major unanswered ethical, social, cultural and legal research questions or gaps that, if adequately answered, could result in substantial improvements in HIV prevention [i.e. reduced transmission] (invited speaker). World AIDS Conference, Toronto, August 2006.

59. Singh JA. International Humanitarian Law and dual loyalty obligations (invited speaker). 8th Course on International Law of Armed Conflict organized by the International Committee of Military Medicine, Spiez, Switzerland, August 2006.
60. Singh JA. Withholding surgery and treatment in HIV positive patients (invited speaker). HIV roundtable symposium: cardiothoracic surgery on HIV positive patients. Durban, South Africa, August 2006.
61. Singh JA. Major unanswered ethical, social, cultural and legal research questions or gaps that, if adequately answered, could result in substantial improvements in HIV prevention [i.e. reduced transmission] (invited speaker; re-presentation of World AIDS Conference paper to local audience). Durban, South Africa, September 2006.
62. Singh JA. Public engagement: who, what, why, when, how? (symposium organizer and speaker). Grand Challenge #9 symposium on ethical, social, cultural and economic issues, Gates Grand Challenges 2nd Annual Meeting, Washington, USA, October 2006.
63. Singh JA. An overview of the key regulatory developments in 2006 relevant to Grand Challenge #9 projects in Africa (symposium organizer and speaker). Grand Challenge #9 symposium on ethical, social, cultural and economic issues, Gates Grand Challenges 2nd Annual Meeting, Washington, USA, October 2006.
64. Singh JA. Public engagement: who, what, why, when, how? (invited speaker). Grand Challenge #6 (PI: Kauffman) collaborators annual meeting, Kampala, Uganda, November 2006.
65. Singh JA. What constitutes community engagement? (invited speaker). Grand Challenges in Global Health Initiative: Grand Challenge #6 (PI: Kauffman) collaborators annual meeting, Kampala, Uganda, November 2006.
66. Singh JA. Ancillary care responsibilities of researchers. (invited speaker). Grand Challenges in Global Health Initiative: Grand Challenge #6 (PI: Kauffman) collaborators annual meeting, Kampala, Uganda, November 2006.
67. Singh JA. Controlling XDR-TB: legal and ethical considerations (Invited speaker). Grand Rounds presentation, Mandela School of Medicine, Durban, South Africa, November 2006.
- 2007**
68. Singh JA. Cassava and biodiversity. (invited speaker). Cassava Consortium Meeting, Danforth Centre, St Louis, USA, January 2007.
69. Singh JA. Addressing Ethical, Social, and Cultural Issues related to the Grand Challenges in Global Health Initiative: Grand Challenge #9 activities (invited speaker). Grand Challenge #9 investigators meeting, Nairobi, Kenya, April 2007.
70. Singh JA. Health, race, and wealth disparities in South Africa 13 years after democracy: how the government and civil society is responding (invited speaker). Convergence of Health and Law Conference, Toronto, Canada, May 2007.
71. Singh JA. Humanitarian medicine and malpractice. Médecins Sans Frontières (Switzerland) Annual General Meeting, Geneva, Switzerland, May 2007.
72. Singh JA. An overview of the Bill and Melinda Gates Foundation, the Grand Challenges in Global Health (GCGH) Initiative, and the Ethical, Social, and Cultural Program of the GCGH (invited speaker). Embrapa Seminar, Brasilia, Brazil, June 2007.

73. Singh JA. Emergency medicine and informed consent: ethical and legal considerations (invited speaker). Emergency Medicine Update symposium, Durban, South Africa, August, 2007.

74. Singh JA. Medical malpractice and emergency medicine / humanitarian work (invited speaker). Emergency Medicine Update symposium, Durban, South Africa, August, 2007.

75. Singh JA. The pitfalls of medical practice (invited speaker). Addington Hospital seminar, Durban, South Africa, October, 2007.

76. Singh JA. Drug-resistant TB: overview of the South African legal framework and policy (invited speaker). 38th Union World Conference on Lung Health, Cape Town, South Africa, November, 2007.

77. Singh JA. Infection Control measures and Individual rights: An ethical dilemma for medical staff (invited speaker). MSF-Switzerland Symposium, Geneva, Switzerland, December, 2007.

2008

78. Singh JA. "Therapeutic Detention" in an age of suspicion: a developing world perspective (invited speaker). University of Toronto Center for Ethics Symposium. Toronto, Canada, February 2008.

79. Singh JA. Use and ownership of tissue (invited speaker). McCords Hospital Seminar, Durban, South Africa, April 2008.

80. Singh JA. Developments in the social sciences and humanities regarding genomics and biotechnology in South Africa (invited speaker). Genome Canada Seminar, Calgary, Canada, May 2008.

81. Singh JA. The interface between health research ethics, public health ethics, and human rights (invited speaker). African Malaria Network (AMANET) Advanced Health Research Ethics Workshop. Dar es Salaam, Tanzania, June 2008.

82. Singh JA. Legal liability of research ethics committees and researchers (invited speaker). African Malaria Network (AMANET) Advanced Health Research Ethics Workshop. Dar es Salaam, Tanzania, June 2008.

83. Singh JA. Using the courts to challenge irrational decisions pertaining to health research (invited speaker). African Malaria Network (AMANET) Advanced Health Research Ethics Workshop. Dar es Salaam, Tanzania, June 2008.

84. Singh JA. Legal liability of MSF's research ethics committees and MSF researchers (invited speaker). MSF Research Ethics Committee and Medical Director's meeting, Barcelona, Spain, July 2008.

85. Singh JA. Gender equity, ethics, health (invited speaker). Intellectual Property and Access to Medicines Certificate Course, Durban, South Africa, July 2008.

86. Singh JA. Global health, global health ethics, and the Millennium Development Goals (invited speaker). Intellectual Property and Access to Medicines Certificate Course, Durban, South Africa, July 2008.

87. Singh JA. Health and human rights (invited speaker). Intellectual Property and Access to Medicines Certificate Course, Durban, South Africa, July 2008.

88. Singh JA. The pitfalls of medical practice (invited speaker). Addington Hospital Seminar, Durban, South Africa, August 2008.

89. Singh JA. Confidentiality and psychiatry (invited speaker). World Psychiatry Day Seminar, Pietermaritzburg, South Africa, October 2008.

90. Singh JA. Health, human rights, and ethics (invited speaker and panelist). WHO/UN Global Ministerial Forum on Research, Bamako, Mali, November 2008.

91. Singh JA. How human rights, health law, and the judiciary can enhance protection of human participants in biomedical research: lessons from South Africa (invited speaker). United Nations Interregional Crime and Justice Research Institute Roundtable of Experts Discussion on African Health Research, Rome, Italy, December 2008.

2009

92. Singh JA. Ethical, legal, social, and cultural challenges in researching XDR-TB (invited speaker). University of Toronto Joint Centre for Bioethics Seminar, Toronto, Canada, February 2009.

93. Singh JA. Post-trial: access to results and availability of outcomes (invited speaker). WHO/UNAIDS workshop on Addressing the Ethical Challenges in Research: working with the revised 'Ethical Considerations in Biomedical HIV Prevention Trials Guidance' and 'Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials', Durban, South Africa, March 2009.

94. Singh JA. Male circumcision as a (compulsory) component of a HIV prevention package in a HIV prevention trial (invited speaker). UNAIDS/ Global Campaign for Microbicides / US Centres for Disease Control Consultation on Standards of Prevention in HIV Prevention Trials, Kampala, Uganda, March 2009.

95. Singh JA. Research ethics: an overview (invited speaker). Department of Surgery Research Day symposium, Albert Luthuli Hospital, Durban, South Africa, April 2009.

96. Singh JA. HIV/AIDS research and the law. Research Ethics Symposium. Nelson Mandela University, Port Elizabeth. South Africa, April 2009.

97. Singh JA. Are we making progress with the current medical and ethical approaches to HIV/AIDS? (invited speaker). University of Zululand Higher Education and Sector HIV and AIDS Conference, Richards Bay, South Africa, May 2009.

98. Singh JA. Mandatory reporting of medical errors: legal implications (invited speaker). KZN Managed Care Coalition Annual Conference, Durban, South Africa, May, 2009.

99. Singh JA. Researching the quarantined and isolated: legal, human rights, ethical, social, cultural, and other implications (invited speaker). World Health Organisation workshop on research ethics in international epidemic response, WHO Headquarters, Geneva, Switzerland, June 2009.

100. Singh JA. Ethical considerations for TB trials in children in resource-limited settings (invited speaker). US National Institutes of Health Workshop on the involvement of children in TB drug development, Washington, USA, July 2009.

101. Singh JA. Material transfer agreements, use of archived samples, and data sharing. 5th MIM Pan-African Malaria Conference, Nairobi, Kenya, November 2009.

102. Singh JA. Embryonic stem cell research: Ethical and legal implications. Media Round Table, MTN Science Centre, Gateway, Durban, South Africa, November 2009.

2010

103. Singh JA. The Limits of Rights? XDR-TB, Public Health and Human Rights (invited speaker). Global Health and Human Rights Speaker Series 2010, University of Toronto, Toronto, January 2010.

104. Singh JA. Contagious diseases, public health ethics and human rights (invited speaker). University of Toronto lecture, Scarborough campus, Toronto, February 2010.

105. Singh JA. Is physician participation in torture ever ethically and legally justifiable? (invited speaker). Managed Care Coalition Annual Symposium, Durban, South Africa, May, 2010.

106. Singh JA. Biosamples: ethical, social, and cultural issues in the context of research in global health (invited speaker), Max Plank Institute, Berlin, Germany, May 2010.

107. Singh JA. Research in humanitarian contexts: ethics considerations (invited speaker). Research to strengthen the public health response in disasters and humanitarian emergencies, Wellcome Trust meeting, London. UK, June 2010.

108. Singh JA. Community engagement in humanitarian contexts (invited speaker). Concept of Community in Bioethics. Wellcome Trust conference, Singapore, July 2010.

109. Singh JA. Post-trial obligations in the aftermath of the world's first successful HIV microbicide trial (invited speaker). University of Minnesota Centre for Bioethics Seminar Series, Minneapolis, USA, September 2010.

110. Singh JA. Shared principles of ethics for infant and young child nutrition in the developing world (invited speaker). Hospital for Sick Children Grand Rounds, Toronto, Canada, September 2010.

111. Singh JA. Intra-consortium data sharing challenges in large multinational, multi-site studies (invited speaker). International data-sharing conference, HeLEX - Centre for Health, Law and Emerging Technologies at Oxford, Oxford University, Oxford, UK, September 2010.

112. Singh JA. Humanitarian organisations and stakeholders (invited speaker). Médecins Sans Frontières Workshop on perception of humanitarian action. Geneva, Switzerland, September/October 2010.

113. Singh JA. Potential implications of the Consumer Protection Act for physicians (invited speaker). South African Medical Association Conference, Pietermaritzburg, October 2010.

114. Singh JA and Bhan A. Deploying new TB diagnostics in India: ethical, social, and human rights implications (invited speaker). Symposium on TB Diagnostics, ICGEB, Delhi, India, December 2010.

2011

115. Singh JA. Ethics and human rights issues in abortion and sterilisation with respect to mentally impaired women and their families (invited speaker). Mental Health Forum/PsySSA Meeting, King George V Hospital, Durban, South Africa, May 2011.

116. Singh JA. Futile care and the rights of surrogate decision-makers in the private sector: ethical and legal issues (invited speaker). Durban Physicians Group, Faculty of Consulting Physicians, (FCPSA), Durban, South Africa, May 2011.
117. Singh JA. Pre-Exposure Prophylaxis for HIV: ethical and legal considerations (invited speaker, Plenary Session). South African National AIDS Conference, Durban, South Africa, June 2011.
118. Singh JA. Medical Male Circumcision: ethical and legal implications (invited speaker). Managed Care Coalition Conference, Durban, South Africa, June 2011.
119. Singh JA. Potential implications of the Consumer Protection Act for speech-language therapists and audiologists (invited speaker). South African National Speech-Language Therapy and Audiology Forum, Durban, South Africa, June 2011.
120. Singh JA. The ethics of managing HIV infection: current and emerging challenges to early treatment initiation. Critical Care Society of South Africa COPICON Conference, Durban, South Africa, July 2011.
121. Singh JA. Health research and policy governance in South Africa (invited speaker). KZN Provincial Government Research Strategic Planning Workshop, Durban, South Africa, August 2011.
122. Singh JA. Emerging ethical issues in HIV prevention trials (invited speaker). McCords Hospital Research Ethics Day Symposium, Durban, South Africa, September 2011.
123. Singh JA. International and local governance of infant nutrition - Social, Ethical, Cultural and Legal Issues (invited speaker). Integrated Nutrition Programme Symposium, Durban, South Africa, October, 2011.

2012

124. Singh JA. Confirmatory trials, phase IIIb trials, implementation trials, phase IV trials, pharmaco-vigilance studies (invited speaker). MSF Ethics Review Board and Medical Directors Meeting, Geneva, March 2012.
125. Singh JA. The participation of minors in research: ethical, social, cultural, and legal challenges (invited speaker). World Health Organisation Seminar, WHO Headquarters, Geneva, Switzerland, May 2012.
126. Singh JA. How to strategically roll out antiretroviral-based interventions for HIV treatment and prevention ethically and judiciously (invited speaker). World Health Organisation Second Expert Consultation Meeting on the Strategic Use of Antiretrovirals, Geneva, Switzerland, May 2012.
127. Singh JA. HIV and advocacy: what do we know how to do but are not doing? (Group rapporteur). Bill and Melinda Gates Foundation HIV Testing and Linkages to Prevention, Care and Treatment Meeting, London, United Kingdom, May-June 2012.
128. Singh JA. Confirmatory trials, phase IIIb trials, implementation trials, phase IV trials, pharmacovigilance studies (invited speaker). United Nations Inter-regional Crime and Justice Institute (UNICRI) training course: Good Clinical Practice in developing settings: the promotion of the international harmonization for the respect of ethical principles, human rights and justice, Mwanza, Tanzania, June 2012.

129. Singh JA. Access to post-trial treatment (invited speaker). United Nations Inter-regional Crime and Justice Institute (UNICRI) training course: Good Clinical Practice in developing settings: the promotion of the international harmonization for the respect of ethical principles, human rights and justice, Mwanza, Tanzania, June 2012.

130. Singh JA. Adolescent HIV treatment and care – terminology governance, human rights, ethical, social, moral, cultural, biological, cognitive and legal considerations (invited speaker). WHO Expert Meeting: Developing guidelines on HIV testing and counselling for adolescents and care for adolescents with HIV (invited). Harare, Zimbabwe, October 2012.

131. Singh JA. Ethics in clinical trials (invited speaker). Treatment Action Group (TAG) TB Community Advisory Board Meeting, Kuala Lumpur, Malaysia, November 2012.

132. Singh JA (invited speaker). Human rights and HIV prevention research (invited speaker). HIV Prevention Trial Network (HPTN) Ethics Working Group Meeting, Public Responsibility in Medicine and Research (PRIM&R) Conference, San Diego, USA, December 2012.

133. Singh JA (invited speaker). Research and Social Injustice: ethics, legal, and human rights perspectives (invited speaker). Public Responsibility in Medicine and Research (PRIM&R) Conference, San Diego, USA, December 2012.

2013

134. Singh JA (invited speaker). Public health systems thinking in developing country settings: challenges and opportunities for public health ethics (invited speaker). Public Health Ethics Workshop, Fondation Brocher, Hermance, Switzerland, February 2013.

135. Singh JA. Managed access of investigational new drugs (invited speaker). Treatment Action Group (TAG) TB Community Advisory Board Meeting, New Delhi, India, April 2013.

136. Singh JA. Compensation for trial-related injuries and deaths: regulatory reforms in India (invited speaker). Treatment Action Group (TAG) TB Community Advisory Board Meeting, New Delhi, India, April 2013.

137. Singh JA. Ethics in clinical trials (invited speaker). Treatment Action Group (TAG) TB Community Advisory Board Meeting, New Delhi, India, April 2013.

138. Singh JA. Ethical, legal, and human rights issues related to offering ART to key populations irrespective of their CD4 count (invited speaker). International AIDS Society (IAS) / World Health Organisation (WHO) meeting on maximizing the treatment and prevention benefits of ART in key populations, Kuala Lumpur, Malaysia, June 2013.

139. Singh JA. Compensation for clinical trial-related injuries and deaths (invited speaker). South African Clinical Research Association Meeting, Durban, South Africa, August 2013.

140. Singh JA. Ethical and legal challenges implicit in researching adolescents (invited speaker). Coalition for Adolescent Girls Meeting, New York City, USA (via tele-video conference), September, 2013.

141. Singh JA. Should surveys qualify for review exemption? (invited speaker). MSF Ethics Review Board and Medical Directors Meeting, Paris, France, September 2013.

142. Singh JA. Mental health and public health diseases: legal and ethical issues (invited speaker). KwaZulu-Natal Clinical Psychology Departments 15th Annual World Mental Health Day Symposium, Pietermaritzburg, Oct 2013.

143. Singh JA. Ethics and human rights in MDR-TB (invited speaker). WHO MDR-TB Stakeholders Meeting: Old problems, new solutions. Paris, France, October 2013.

144. Singh JA. South Africa's experience in addressing ethical and legal barriers for HIV research and service provision for adolescents (invited speaker). Annual Meeting of the UNAIDS Inter-Agency Task Team on HIV and young people (IATT/YP), Cape Town, December 2013.

2014

145. Singh JA. Singh JA. Defining obligations and taking responsibility for stakeholder actions (invited speaker / panelist). Micronutrient Forum Global Conference, Addis Ababa, Ethiopia, June 2014.

146. Singh JA. Ethics considerations in engaging Vulnerable and Marginalized Populations in HIV Prevention Research (invited speaker). Community Working Group meeting, HPTN / IMPAACT Annual Meeting, Washington, DC, USA, June 2014.

147. Singh JA. The ethics of engaging populations at risk (plenary presentation - invited speaker). HPTN / IMPAACT Annual Meeting, Washington, DC, USA, June 2014.

148. Singh JA. Compensation for trial-related injuries and death (invited speaker), South African Clinical Research Conference Johannesburg, September 2014.

149. Singh JA. The Ethical Foundations of Inclusiveness in Homosexuals (invited speaker). Academy of Sciences of South Africa (ASSAf) Expert Panel Meeting on Diversity in Human Sexuality, Bellagio, Italy, September, 2014 (via tele-conference).

2015

150. Singh JA. Post-trial access to PrEP in HIV vaccine trials (invited speaker). HIV Vaccine Trial Network (HVTN) Annual Meeting, Washington, DC, USA, May 2015.

151. Singh JA. Non-voluntary isolation and forced treatment of drug-resistant TB patients (invited speaker). WHO / University of Zurich Meeting on Emerging Ethical and Human Rights Issues in the Treatment and Prevention of the Global Tuberculosis Epidemic, Brocher Foundation, Geneva, Switzerland, May 2015.

152. Singh JA. Distribution of Scarce Investigational Agents (invited speaker). MSF Ethics Review Board and Medical Directors Meeting, Geneva, Switzerland, June 2015.

153. Singh JA. Ethics considerations in engaging Vulnerable and Marginalized Populations in HIV Prevention Research (invited speaker), Community Working Group Meeting, HIV Prevention Trial Network (HPTN) Annual Meeting Washington, DC, USA, June 2015.

154. Singh JA. The importance of risk mitigation plans: why they were specifically needed for HPTN 074 and HPTN 075 (invited speaker), Community Working Group Meeting, HIV Prevention Trial Network (HPTN) Annual Meeting Washington, DC, USA, June 2015.

155. Singh JA. Ethical Issues to Consider in the Design of HIV Prevention Trials Involving Transgender People (invited speaker). HPTN Workshop: Developing HIV Prevention Interventions for Transgender Men and Women, and other Gender Non-Conforming Individuals. HIV Prevention Trial Network (HPTN) Annual Meeting Washington, DC, USA, June 2015.

156. Singh JA. Adolescents and PrEP: ethical and legal challenges (invited speaker). UNICEF / IAS Consultation on Clinical and Operational Considerations for the Implementation of Pre-

Exposure Prophylaxis (PrEP) in Sexually Active Older Adolescents (15-19, Vancouver, Canada, July 2015.

157. Singh JA. Review of the Law and HIV: gaps and guidance (invited speaker). South African National AIDS Council (SANAC) Meeting, Pretoria, South Africa, September 2015.

158. Singh JA. Why Human Health and Health Ethics Must Be Central to Climate Change Deliberations (invited speaker). Public Health Medicine Journal Club, University of KwaZulu-Natal, Durban, South Africa, November 2015.

159. Singh JA. Post-trial access: the case of HIV and Pre-Exposure Prophylaxis (invited speaker). Public Responsibility in Medicine and Research (PRIM&R) Annual Advancing Research Ethics Conference, Boston, USA, November 2015.

160. Singh JA. The research of children in South Africa: regulatory overview (invited speaker). Africa Centre Symposium on researching adolescents, Durban, South Africa, November 2015.

2016

161. Singh JA. The ethical and legal implications of HIV misdiagnosis (false positives and false negatives) (invited speaker – presentation delivered by proxy). WHO consultation on the social, public health, and human rights implications of misdiagnosis of HIV status, Geneva, Switzerland, March 2016.

162. Singh JA. Medical aspects related to documentation and ethical behaviour in the health field (invited speaker), King George V / King Dinizulu Hospital Symposium, Durban, South Africa, March 2016.

163. Singh JA. The child patient and the legal aspects associated with treatment and care of children (invited speaker). South Africa Society of Psychiatrists, KZN Symposium, Durban, South Africa, April 2016.

164. Singh JA. Can Adolescents be successfully Included in HIV Prevention Trials? [debate format] (invited speaker). IMPAACT Annual Meeting Plenary Session, Washington, DC, USA, June 2016.

165. Singh JA. Review of the law and HIV: gaps and guidance (invited speaker). South African National AIDS Council (SANAC) Meeting, Johannesburg, South Africa August 2016.

166. Singh JA. Ethics, Law and Innovation in global health. The ethics and legality of employing genetically modified vectors against vector-borne diseases (invited speaker). 6th Global Health Education Initiative, Postgraduate Medical Education, Faculty of Medicine, Alumni Alliance Event, University of Toronto, Toronto, Canada, September 2016.

167. Singh JA. The ethics of gene drive technology (invited speaker). The First Consultative Meeting on Regulatory Capacity Building in West Africa on Gene Drive Technology. Accra, Ghana, October 2016.

168. Emerson C and Singh JA. Ethical Issues Related to Gene Drive Research (invited speakers). Funders Consultation on Gene Drive Research (Bill & Melinda Gates Foundation, Foundation for the National Institutes of Health, Wellcome Trust), Grand Challenges Annual Meeting, London, UK, October 2016.

169. Singh JA. Ethical, social, and cultural factors that hinder adolescents' access to sexual and reproductive healthcare services: international review (invited speaker). UNICEF / Southern

African AIDS Trust (SAT) Age of Consent Validation Meeting, Johannesburg, South Africa, October 2016.

170. Singh JA. Ethics for consent for HIV testing and other biomarkers, and return of results (invited speaker). WHO National Population-based Survey Guidance Update Meeting, Geneva, Switzerland, November 2016.

2017

171. Singh JA. Informed consent: the consent form and its associated legalities (invited speaker). King Dinizulu Hospital Symposium, Durban, South Africa, February 2017.

172. Singh JA. Vector Control and gene drive: reflections from an ethicist (invited speaker). WHO Scoping meeting on the ethics of vector-borne disease. Geneva, Switzerland, February 2017.

173. Singh JA. Ethical and legal considerations in the design and conduct of phylogenetic studies (invited speaker). ARESA Symposium, Cape Town, South Africa, May 2017.

174. Singh JA. Social sciences, behavioural sciences, and humanities: implications for HIV cure research (invited speaker). International AIDS Society (IAS) 2017 HIV Cure Global Research Academy, Wits Rural Facility, Bushbuckridge, Mpumalanga, South Africa, May 2017.

175. Singh JA. How domestic policies in major donor countries can impact on global health (invited speaker). 7th Global Health Education Initiative, Postgraduate Medical Education, Faculty of Medicine, Alumni Alliance Event, University of Toronto, Toronto, Canada, September 2017.

177. Singh JA. Vector-borne diseases and gene drive (invited speaker). Bioethics Seminar Series, University of Minnesota, Minneapolis, USA, September 2017.

179. Singh JA. Considerations for Protection of Volunteers (invited speaker). HIV Prevention Trial Network (HPTN) African Regional Meeting, Johannesburg, South Africa, 18 October 2017.

180. Singh JA. Ethics & Law considerations for standard of care – case study of PrEP (invited speaker). South African Medical Research Council Standard of Care in Clinical Research Summit, Cape Town, South Africa, November 2017.

181. Singh JA. Sharing and publicizing the Stakeholder Engagement Best Practices guidance document: factors to consider (invited speaker). Stakeholder Engagement Best Practices for Novel Vector Control Methods, Reston, Virginia, USA, November 2017.

2018

182. Singh JA. Medical Malpractice and Professional Negligence (invited speaker). 37th National Congress of the South African Society of Obstetrics & Gynaecologists (SASOG), Durban, South Africa, March 2018.

183. Singh JA. The foetus as a patient – legal implications (invited speaker). 37th National Congress of the South African Society of Obstetrics & Gynaecologists (SASOG), Durban, South Africa, March 2018.

184. Singh JA. Ethical issues associated with vector-borne diseases: research guidance points (invited speaker). World Health Organisation Ethics and vector-borne diseases International Consultation. Vienna, Austria, May 2018.

185. Singh JA. Ethical issues to consider in HIV cure research (invited speaker). International AIDS Society (IAS) HIV Cure Research with the Community Workshop, Amsterdam, Netherlands, July 2018.

186. Singh JA. Vulnerability - the inclusion of pregnant women in clinical trials (invited speaker). South African Clinical Trial Research Association (SACRA) KwaZulu-Natal Regional Workshop, Durban, South Africa, July 2018.

187. Singh JA. The ethics of cosmetic dermatology (invited speaker). Dermatology for Africa 2018 Congress, Durban, South Africa, August 2018.

188. Singh JA. Ethical and legal challenges of conducting sexuality research on adolescents: gaps and guidance (invited speaker). University of Toronto's Joint Centre for Bioethics Seminar Series, Toronto, Canada, September 2018.

189. Singh JA. Finding a Cure for HIV: the history, politics and current status of engaging the world towards a cure (invited speaker). Post-Graduate Medical Education Global Health Special Lecture Event, University of Toronto, Toronto, Canada, September 2018.

190. Singh JA. Enhancing medical male circumcision uptake amongst men and adolescents through economic incentives: ethical, legal, and human rights dimensions (invited speaker). Meeting of the WHO Guideline Development Group on new and updated guidance on male circumcision for HIV prevention. Johannesburg, South Africa, November 2018.

191. Singh JA. Circumcision in adolescents 10-14 years of age for HIV prevention: ethical, legal, and human rights considerations (invited speaker). Meeting of the WHO Guideline Development Group on new and updated guidance on male circumcision for HIV prevention. Johannesburg, South Africa, November 2018.

192. Singh JA. Considerations on stakeholder engagement in the development and testing of gene drive applications (invited speaker). Guidance for development of gene drive applications - Fourteenth meeting of the Conference of the Parties to the Convention on Biological Diversity (CBD COP 14), Sharm El-Sheikh, Egypt, November 2018.

193. Singh JA. Ethical Issues to Consider in the Design of HIV Prevention Trials Involving Transgender People (invited speaker). HPTN 091: Integrating HIV Prevention, Gender-Affirmative Medical Care, and Peer Health Navigation to Prevent HIV Acquisition and HIV Transmission for Transgender Women: A Vanguard Feasibility and Acceptability Study Protocol Development Meeting, Durham, North Carolina, United States (via teleconference), January 2019.

194. Singh JA. Scientific Integrity (invited speaker). UKZN / Harvard Research Training State of the Art Lecture, Durban, South Africa, February 2019.

195. Singh JA. Reflections on Science Diplomacy and Advocacy in Africa - Ethical, Social, and Cultural (ESC) issues within the Context of Emerging Technologies (invited speaker). African Union Calestous Juma Executive Dialogue on Innovation and Emerging Technologies, Johannesburg, South Africa, March 2019.

196. Singh JA. Engagement with Public, Stakeholders and Communities - Communications, Outreach and Advocacy: case studies (invited speaker). African Union Calestous Juma Executive Dialogue on Innovation and Emerging Technologies, Johannesburg, South Africa, March 2019.

197. Singh JA. Compensation for research-related injuries in South Africa (invited speaker). 8th Annual ARESA Research Ethics Seminar, Cape Town, South Africa, April 2019.

198. Singh JA. How South Africa's human rights framework is shaping and facilitating the global HIV research and programmatic agenda (invited speaker). Global Health Law Conference, Cape Town, South Africa, April 2019.
199. Singh JA. The Internet, social media, and adolescent sexual health: emerging ethical issues (invited speaker). Ethical issues in research & programming with vulnerable young adolescents, World Health Organisation, Geneva, April 2019.
200. Singh JA. Research, ethics, and vector-borne diseases (invited speaker). Ethics and Vector-borne diseases International Consultation, World Health Organisation, Geneva, July 2019.
201. Singh JA. Artificial Intelligence and Global Health: a Southern perspective (invited speaker). Post-Graduate Medical Education Global Health Special Lecture Event, University of Toronto, Toronto, Canada, September 2019.
202. Singh JA. Social media and research: ethical and legal considerations (invited speaker). MSF Ethics Review Board and Medical Directors Meeting, Barcelona, Spain, October 2019.
203. Singh JA. Overview of the WHO Guidance On Ethical Considerations in Designing and Conducting Research on Sexual and reproductive health in adolescents (invited speaker). 24th Congress of the World Association for Sexual Health, Mexico City, Mexico, October 2019.
204. Singh JA. Communications, Outreach and Advocacy: case studies (invited speaker). Bill and Melinda Gates Foundation Grand Challenges in Global Health Annual Meeting, Addis Ababa, Ethiopia, October 2019.
205. Singh JA. The art of science advocacy: Increasing R&D investments – a case study from South Africa (invited speaker). Bill and Melinda Gates Foundation Grand Challenges in Global Health Annual Meeting, Addis Ababa, Ethiopia, October 2019.
206. Singh JA. Why Human Health and Health Ethics Must Be Central to Climate Change Deliberations (invited speaker). Research and Public Health Ethics Certificate Course, Centre of Biomedical Ethics and Culture / Kenya Medical Research Institute Bioethics Training Initiative, Nairobi, Kenya, October 2019.
207. Singh JA. Health policy and health systems research: ethical issues (invited speaker). Research and Public Health Ethics Certificate Course, Centre of Biomedical Ethics and Culture / Kenya Medical Research Institute Bioethics Training Initiative, Nairobi, Kenya, October 2019.
208. Singh JA. Health policy and health systems research: ethical issues (invited speaker). Distribution of scarce investigational agents. Research and Public Health Ethics Certificate Course, Centre of Biomedical Ethics and Culture / Kenya Medical Research Institute Bioethics Training Initiative, Nairobi, Kenya, October 2019.
209. Singh JA. Gene drive research on vector-borne diseases: Ethics considerations (invited speaker). Research and Public Health Ethics Certificate Course, Centre of Biomedical Ethics and Culture / Kenya Medical Research Institute Bioethics Training Initiative, Nairobi, Kenya, October 2019.
210. Singh JA. Ethical Issues in Research with Adolescent Minors: The Ethical Review Board Perspective (invited speaker - webinar). Global Early Adolescents Study (GEAS) Ethics Webinar, Johns Hopkins University, Baltimore, USA, November 2019.
211. Singh JA. Ethical considerations for HIV prevention research: view from a Prevention Trials Network (invited speaker). UNAIDS Consultation on ethical considerations for

HIV prevention research in the era of highly effective HIV prevention, Montreux, Switzerland, November 2019.

212. Singh JA. Vaccines and pregnant women: liability and risk mitigation (invited speaker). World Health Organisation Consultation on ethics surrounding vaccines and pregnant women, Geneva, Switzerland, December 2019.

2020

213. Singh JA. Vector control methods and global health (invited speaker). Vector-Borne Diseases, Nature and Genome Editing: An Ethical Consultation. Medical University of Vienna / UNESCO Austrian Commission / Center of Medical Research Lambaréné (CERMEL, Gabon) / Association for Responsible Research and Innovation in Genome Editing (ARRIGE), Vienna, Austria, January 2020.

214. Singh JA. Opportunities and challenges with use of AI in low and middle income countries (invited speaker). Developing WHO Guidance on Ethics & Governance of Artificial Intelligence (AI) for Health, Copenhagen, Denmark (virtual meeting because of COVID-19), March 2020.

215. Singh JA. COVID-19: perspectives from South Africa (invited speaker). COVID-19 from a Global Health Perspective. Global Health Education Initiative symposium series, Faculty of Medicine, University of Toronto, Toronto, Canada (virtual meeting because of COVID-19), April 2020.

216. Singh JA. Social media and research: ethical and legal considerations (invited speaker). MSF. Day Before Scientific Days Research and Ethics Workshop 2020. MSF, London, UK (virtual meeting because of COVID-19), May 2020.

217. Singh JA (co-presenter: Venkatraman C). Guidance on ethical considerations in planning and reviewing research studies on sexual and reproductive health in adolescents (invited speaker). World Congress on Bioethics, Pennsylvania, USA, (virtual conference because of COVID-19), June 2020.

218. Singh JA. Ethico-legal implications of treatment interruption in HIV cure research (invited speaker). Pathways to an HIV cure: tools for community and clinicians. Pre-conference to the International AIDS Society 23RD International AIDS 2020 Conference, San Francisco, USA, (virtual conference because of COVID-19), July 2020.

219. Singh JA. AI usage and the importance of capacity building in health services – an ethical perspective (invited speaker). Society of Radiographers of South Africa (SORSA) first virtual Symposium on Artificial Intelligence, Durban, South Africa (virtual conference because of COVID-19), August 2020.

220. Singh JA. COVID-19: nationalism and exceptionalism undermines global health (invited speaker). University of Minneapolis Center for Bioethics Ethics Grand Rounds, Minneapolis, USA (virtual conference because of COVID-19), September 2020.

221. Singh JA. Ethical considerations when conducting HIV research during the COVID-19 pandemic. Meeting the Challenge: Multi-disciplinary perspectives on conducting HIV Biomedical Research during the COVID-19 Global Pandemic (invited speaker; webinar because of COVID-19), US NIH webinar, Bethesda, USA, November 2020.

222. Singh JA. Is there an ethical requirement to unblind a trial if an unlicensed vaccine is potentially locally available to participants? WHO ad hoc consultation. Next steps for COVID-19 vaccine clinical evaluation (invited speaker; virtual conference because of COVID-19), Geneva November 2020.

2021

223. Singh JA. Vaccine Ethics and COVID-19 – South Africa's COVID-19 vaccine strategy (invited speaker). George Washington University, Washington, DC, USA, January 2021 (online webinar).
224. Singh JA. South Africa: one year after its first COVID-19 case (invited speaker). Global Health Education Initiative symposium series, Faculty of Medicine, University of Toronto, Toronto, Canada (virtual meeting because of COVID-19), April 2021.
225. Singh JA. Epidemic Ethics: Challenges and ethical implications of distinguishing between research and rollout in pandemic responses (invited speaker). PHEPREN (Public Health Emergency Preparedness and Response Ethics Network), Geneva, Switzerland, May 2021. <https://epidemicethics.tghn.org/seminars/> (webinar)
226. Singh JA. COVID-19 vaccines: How macro-level factors can vitiate autonomy at the individual level can vitiate personal autonomy (invited speaker). Science, Law, and decision-making. Power and the COVID-19 Pandemic Webinar Series, Middlesex University, London, UK, May 2021 (webinar).
227. Singh JA. Resilience, Compassion, Lessons Learned: Global Health Governance (invited speaker). 8th Annual University of Toronto Post-Graduate Medical Education Global Health Day on Resilience and Compassion: Lessons Learned during a Global Pandemic, Toronto, Canada, May 2021 (online because of COVID-19)
228. Singh JA. The POPIA Code of Conduct for research: complexities of sector inclusions and exclusions (invited speaker). ASSAf POPIA Public Consultation Forum, Pretoria, South Africa, May 2021 (online consultation).
229. Singh JA. Research ethics in a pandemic context (invited speaker). Research & Innovation in the Post-COVID Period. 6th Universities South Africa Research and Innovation Strategy Group (RISG) Research & Innovation Biennial Dialogue, Pretoria, June 2021 (online because of COVID-19).
230. Singh JA. Opportunities to collaborate: science advice (invited speaker). COVID-19 Africa Rapid Grant Fund (CARGF) First Grant-holder Workshop, Pretoria, June 2021 (online because of COVID-19).
231. Singh JA. Placebo-controlled COVID-19 vaccine trials (invited speaker). World Health Organization Access to COVID-19 Tools Accelerator Ethics and Governance Working Group, Geneva (online meeting), August 2021.
232. Singh JA. Placebo-controlled COVID-19 vaccine trials (invited speaker). World Health Organization COVID-19 Ethics Working Group, Geneva, September 2021 (online meeting).
233. Singh JA. SAGE overview (invited speaker). National Disaster Management Forum Meeting, Pretoria, South Africa, Sept 2021 (online meeting).
234. Singh JA. Protection of Personal Information Act: how does POPIA impact on research during a pandemic? (invited speaker). ARESA (Advancing Research Ethics Training in Southern Africa) Seminar, Stellenbosch University, Stellenbosch, South Africa, September 2021 (online because of COVID-19).
235. Singh JA. Ethical issues to consider in HIV cure research (invited speaker). International AIDS Vaccine Initiative (IAVI) Research Ethics Seminar, IAVI Leadership Development Program, Nairobi, Kenya October 2021 (online because of COVID-19).

236. Singh JA. HIV-1 reservoir research: ethics issues in autopsies (invited speaker). International AIDS Vaccine Initiative (IAVI) Research Ethics Seminar, IAVI Leadership Development Program, Nairobi, Kenya October 2021 (online because of COVID-19).
237. Singh JA. Ethics in HIV PrEP research (invited speaker). International AIDS Vaccine Initiative (IAVI) Research Ethics Seminar, IAVI Leadership Development Program, Nairobi, Kenya, October 2021 (online because of COVID-19).
238. Singh JA. Off-label drug use for COVID-19: ethical and legal implications (invited speaker). 16th Annual International Conference on Clinical Ethics & Consultation, Stellenbosch, South Africa, November 2021 (online because of COVID-19).
239. Singh JA. SAGE overview (invited speaker). Western Cape Provincial Disaster Management Advisory Forum, Cape Town, South Africa, November 2021 (online meeting)

2022

240. Singh JA. Cognitive Capacity and Understanding of Risk/Benefit of Research in Adolescents in Resource Limited Settings (invited speaker). US National Institute of Child Health and Human Development (NICHD) Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings (PATC³H) Network virtual annual meeting, Washington, DC, USA, February 2022 (online event).
241. Singh JA. Research and ethics (invited speaker). WHO Global Research and Innovation Forum, Geneva, 24-25 February 2022 (online event). <https://www.who.int/news-room/events/detail/2022/02/24/default-calendar/covid-19-global-research-and-innovation-forum-an-invitation-to-the-research-community>
242. Singh JA. Legal considerations for data transfer agreements (invited speaker). REDSSA (Research for Ethical Data Science in Southern Africa) Seminar on the Ethical, Legal and Social Implications (ELSI) of Data Science in Healthcare in Sub-Saharan Africa, Stellenbosch, South Africa, April 2022 (live event but participated online).
243. Singh JA. Defending the oceans commons (invited speaker). Climate Justice Charter Movement World Earth Day event, April, 2022 (online event).
244. Singh JA. Randomised control trials: ethical implications of placebo use in HIV prevention research (invited speaker). HIV Prevention Trial (HPTN) Annual Meeting, Washington, DC, USA, June 2022).
245. Singh JA. Scientific, ethical, and regulatory considerations for paediatric COVID-19 vaccine trials (invited speaker). Mini-Symposium: Paediatric Academic Program, Stellenbosch University, Stellenbosch, South Africa 22 June 2022 (online event).
246. Singh JA. Reviewing adaptive clinical trials: some reflections (invited speaker). 13th Global Summit of National Bioethics Committees, Lisbon, Portugal, September 2022.
244. Singh JA. Climate change, health, and ethics (invited speaker). 13th Global Summit of National Bioethics Committees, Lisbon, Portugal, September 2022.
247. Singh JA. Experimental medicine - ethics considerations (invited speaker). Building regulatory and ethics expertise for Experimental Medicine: International AIDS Society (IAS) Webinar (online event), September 2022.
248. Singh JA. Artificial intelligence and health research: ethics and regulatory considerations (invited speaker). REDSSA Seminar on the Ethical, Legal and Social Implications (ELSI) of Data

Science in Healthcare in sub-Saharan Africa, Stellenbosch, South Africa (live event but participated online), October 2022.

2023

249. Singh JA. Climate change, human health and ethics (invited speaker). 13th Global Summit of National Ethics Committees. Lisbon, Portugal, September 2022.

250. Singh JA. Post-trial access ethics considerations: long-acting Cabotegravir (invited speaker). Hot Topics in Research Ethics - Post Trial Responsibilities and Access to Injectable Cabotegravir for PrEP. University of Malaysia-Johns Hopkins University Webinar (online), April 2023.

251. Singh JA. Phase 1 trials involving healthy volunteers: evolving trial designs and ethics norms (invited speaker). 2nd Global meeting of the Volunteers in Research (VoiR) Ethics Initiative, European Commission, Covent Garden premises, Brussels, Belgium, April 2023.

252. Singh JA. Why extreme heat events and associated phenomena are a health and ethics issue. Oxford Global Health and Bioethics International Conference 2023, Oxford University, Oxford, UK, June 2023.

253. Singh JA. Wastewater management in South Africa: where to from here. Cholera outbreak: What you need to know about the disease, its spread and a potential action plan to fight the nationwide outbreak (invited speaker). Academy of Science of South Africa (ASSAf) Webinar, August 2023.

254. Singh JA. Anonymisation, pseudo-anonymisation, and de-identification: Implications for international collaborators (invited speaker). REDSSA (Research for Ethical Data Science in Southern Africa) Seminar on Generative AI and data science: Ethical, Legal and Social Issues (ELSI) – challenges and opportunities for health research in Sub-Saharan Africa (SSA), Stellenbosch, South Africa, October 2023 (live event but participated online).

255. Singh JA. Deferred consent (invited speaker). MSF Ethics Review Board and Medical Directors Meeting, Geneva, Switzerland, October 2023.

256. Singh JA. Secondary use of data and samples (invited speaker). MSF Ethics Review Board and Medical Directors Meeting, Geneva, Switzerland, October 2023.

257. Singh JA. Wildfires (invited speaker). Science Forum South Africa 2023, Pretoria, South Africa, December 2023.

Poster presentations

1. Pinto A and Singh JA. Community engagement in microbicide trials. World AIDS Conference, Mexico City, Mexico, August 2008.

Other academic / research activities

(Post-2005 only)

2005

1. Session chair: Global Forum for Bioethics: What happens when the research is over? Wellcome Trust Symposium, Malawi, March 2005.

2. Contributor: drafting of the Kampala Compact. 1st Workshop on the Global Bargain for Bio-security and Health, New York Academy of Sciences, New York, USA, November 2005.

3. Session chair: Addressing Social, Cultural and Ethical Issues in the Grand Challenges in Global Health Initiative, Bill and Melinda Gates Foundation, Seattle, USA, November 2005.

4. Session chair: Informed consent in genetic epidemiology malaria research, Gates Grand Challenges Project, Bamako, Mali, February 2006.

2006

5. Session chair: World AIDS Conference, Mexico City, Mexico, August 2006.

2007

6. Symposium organiser and session chair: Gates Foundation Grand Challenges in Global Health Initiative, Grand Challenge #9 meeting on socio-economic issues, Cape Town, South Africa, October 2007.

2009

7. Plenary session chair: South African National AIDS Conference, Durban, South Africa, April 2009.

8. Plenary session chair: World Health Organisation (WHO) meeting on research ethics in international epidemic response, WHO Headquarters, Geneva, Switzerland, June 2009.

9. Plenary session chair: An emergency public health response to the combined DR-TB and HIV-AIDS crisis in the Southern African region, MSF International Consultative Workshop. Manzini, Swaziland, October, 2009.

10. Panelist: Social, ethical, and cultural issues. 4th Annual Meeting of the Grand Challenges in Global Health Initiative (Bill and Melinda Gates Foundation), Arusha, Tanzania, October 2009.

2010

11. Plenary session chair: International Data Sharing Conference, Oxford University, Oxford University, UK, September 2010.

2011

12. Session chair. Bioethics Challenges in HIV/AIDS Research, NIH/NIAID/Division of AIDS, Bethesda, USA, October 31- November 1, 2011

2013

13. Plenary session chair: 6th South African National AIDS Conference, Durban, South Africa, June 2013.

14. Workshop chair: HIV and access to critical care. 6th South African National AIDS Conference, Durban, South Africa, June 2013.

2014

15. Panelist: Micronutrient Forum Global Conference, Addis Ababa, Ethiopia, June 2014.

2015

16. Panelist: Columbia University ICAP symposium: Achieving Quality & Demonstrating Impact in Global HIV Programs, Vancouver, Canada, July 2015.

17. Panelist: AIDS Vaccine Advocacy Coalition (AVAC) Satellite meeting: Injectable Options and Preventable Confusion: an updated and interactive discussion on the pipeline of antibodies, long-acting ARVs and vaccines, International AIDS Society (IAS) Conference, Vancouver, Canada, July 2015.

18. Panelist: From Ideal to Real: Post-Trial Access, Expanded Access, and Use of Ancillary Treatments in Global Studies, Public Responsibility in Medicine and Research (PRIM&R) Annual Advancing Research Ethics Conference, Boston, USA, November 2015.

2016

19. Panelist: Are there modifications to the design of HOPE that would inform decisions about further support for the current dapivirine ring, and/or future microbicide product development (joined remotely). US NIH (DAIDS, NIAID) Consultation on ASPIRE/MTN-020 and HOPE/MTN-025, Rockville, Maryland, USA, March 2016.

20. Panelist: Roundtable Session: Bridging Biomedical Research and Social Sciences. Towards an HIV Cure Symposium, 21st International AIDS Conference, Durban, South Africa, July 2016.

21. Panelist: Understanding HIV Cure, Global Village Workshop, Towards an HIV Cure Symposium, International AIDS Conference, Durban, South Africa, July 2016.

2017

22. Session chair: Ensuring Efforts to Scale up, Strengthen and Sustain HIV Responses, Joep Lange Institute, Amsterdam, The Netherlands, September 2017.

23. Session chair of panel discussion: Regulatory/Ethics/Legal considerations in establishing standard of care in clinical trials. South African Medical Research Council Standard of Care in Clinical Research Summit, Cape Town, South Africa, November 2017.

2018

24. Panelist: The Faithful on Artificial Life Support and End of life. Critical Care Society of Southern Africa (CCSSA) Annual Congress, Durban, South Africa, August 2018.

25. Session co-chair: Enhancing uptake of Medical Male Circumcision: economic compensation. WHO Guideline Development Group on new and updated guidance on male circumcision for HIV prevention, Johannesburg, South Africa, November 2018.

26. Session co-chair: Enhancing uptake of Medical Male Circumcision: younger adolescents. WHO Guideline Development Group on new and updated guidance on male circumcision for HIV prevention, Johannesburg, South Africa, November 2018.

2019

27. Panelist: Litigation in Research. 8th Annual ARESA Research Ethics Seminar, Cape Town, South Africa, April 2019.

28. Panelist: Genetically-based vector control for malaria elimination. Bill and Melinda Gates Foundation Grand Challenges in Global Health Annual Meeting, Addis Ababa, Ethiopia, October 2019.

2020

29. Panelist: Which way to go? Is it ethically acceptable to fight vector borne diseases via genome editing (gene drive)? Vector-Borne Diseases, Nature and Genome Editing: An Ethical Consultation. Medical University of Vienna / UNESCO Austrian Commission / Center of Medical Research Lambaréné (CERMEL, Gabon) / Association for Responsible Research and Innovation in Genome Editing (ARRIGE), Vienna, Austria, January 2020.

30. Panelist: MSF Scientific Day International Conference. Ethics of social media use in health promotion and health programming – emerging thinking, challenges, and opportunities. London, May 2020 (online conference because of the COVID-19 pandemic).

31. Panelist: Global Forum for Bioethics in Research (GFBR) and Public Health Emergency Preparedness and Response Ethics Network (PHEREN) Symposium. Ethics of adaptive trial designs. London / Geneva, November 2020 (online symposium because of the COVID-19 pandemic).

2021

32. Panelist: World Health Organization Ad Hoc Consultation on COVID Vaccines. Methodological approaches to assess variants effect on vaccine efficacy, effectiveness and impact. (session topic: What are the benefits and challenges of generating randomized evidence during vaccine deployment? Geneva, Switzerland, February 2021 (online global consultation because of the COVID-19 pandemic).

33. Panelist: MSF Scientific Days International Conference. Community-centred programming. London, May 2021 (online conference because of the COVID-19 pandemic).

34. Panelist: Expert Briefing: Policy Challenge II - WTO & COVAX (Master in Public Policy, Oxford University, UK), May 2021 (online session).

35. Panelist: International AIDS Society (IAS) and UNAIDS Satellite Conference. An HIV vaccine: who needs it? July 2021 (online conference because of the COVID-19 pandemic).

36. Session co-chair. Pandemic research: Drawing from Lessons Learnt During the Sisonke Study. South African Medical Research Council Bioethics Advisory Panel Seminar. September 2021 (online event).

37. Disaster Risk Management Fire & Emergency Services Assessment. South African Local Government Association (SALGA)-Academy of Science of South Africa (ASSAf) Seminar: Disaster Risk Management Fire & Emergency Services Assessment, November 2021.

38. Panelist: Conversations at the Intersection of Ethics and Policy. World Health Organisation Pandemic Ethics & Policy Summit, December 2021 (online event).
<https://www.youtube.com/watch?v=O-SpMod2vYA>.

39. Panel session chair: Is there a case to be made for COVID-19 Vaccinations in Children? South African Medical Research Council Bioethics Advisory Panel Seminar. December 2021 (online event).

2022

40. Chair and Facilitator: Is COVID-19 over? Or is it still lurking in the shadows? An African response to the pandemic. Higher Education Media Services Webinar. July 2022 (online event).

41. Panelist. Plenary Panel Discussion: Facing the pandemic: roles and responsibilities of ethicists in COVID-19 Task Force and Ethics Committees. 16th World Congress of Bioethics, Basel, July 2022 (participated remotely).

42. Panelist: Ethical responses to Ebola: applying lessons learned. Public Health Emergency Preparedness and Response Ethics Network (PHEREN) Symposium, November 2022 (virtual event).

2023

43. Chair: Scientific Advisory Group on Emergencies (SAGE), Academy of Science of South Africa (ASSA) webinar on extreme heat and health (Part 1), March 2023 (virtual event).

44. Panelist: Next Gen HIV Prevention Research: Clinical trials in an era of highly effective standards of care. Satellite session. World AIDS Conference (International AIDS Society [IAS] Conference on HIV Science, Brisbane, Australia, July 2023 (participated virtually).

45. Panelist: Difficult/unusual issues in HIV biomedical prevention research including next-generation emerging trial designs. International AIDS Vaccine Initiative (IAVI) India-Africa virtual workshop, ADVANCE (Accelerating the development of vaccines and new technologies to combat the AIDS epidemic) Program, December 2023 (virtual workshop).

Academic outreach initiatives

Engagement in popular media / audio-visual / multi-media

2000

1. Durban, South Africa: Live radio interview: Medical Malpractice. *Legal-Online*: Radio Lotus: 8.30pm-10.00pm (July 04, 2000).

2. Durban, South Africa: Live radio interview: Euthanasia. *Legal-Online*: Radio Lotus: 8.30pm – 10.00pm, (August 01, 2000).

2002

3. Durban, South Africa: Pre-recorded radio interview: Human organ sales. *Newswatch*: East-Coast Radio: 12.30pm; 1.30pm; 2.30pm (August 13, 2002).

2004

4. Johannesburg, South Africa: Live television debate: Why reproductive human cloning should be permitted. *The Big Question*: SABC 2: 12pm-1pm, July 11, 2004.

5. Durban, South Africa: Newspaper interview: The importance of ethics in research: *Daily News*: July 23, 2004.

6. Durban, South Africa: Newspaper interview: The importance of ethics in research – *IsiZulu* translation: *Isolezwe*: July 26, 2004.

7. Durban, South Africa: Live radio interview: Confidentiality and disclosures in health care practice. *Medical Ethics*: Radio Al Ansar: 3-4pm, September 04, 2004.

2005

8. Durban/Johannesburg, South Africa: Radio interview on the patenting of human genes - ethical and legal implications: *SAFM*: 9-10pm, November 14, 2005.

2006

9. Toronto, Canada: Interview on the Grand Challenges in Global Health Initiative. *Research and Innovation at the University of Toronto*, Spring 2006: 7(2). Accessible: <http://www.research.utoronto.ca/edge/spring2006/1.html>

2007

10. Geneva, Switzerland: MSF webcast interview: XDR-TB: <http://www.msf.ch/index.php?id=892>: MSF Switzerland, Geneva, December 20, 2007.

2008

11. Durban, South Africa: Live radio interview: The ethics and legality of involuntary detention for non-compliant XDR-TB patients. *Radio 702*: 10.30-10.40am, January 17, 2008.

2009

12. Toronto, Canada: University of Toronto Joint Centre for Bioethics (JCB) seminar webcast: Researching XDR-TB: Ethical, Legal, Social and Cultural Challenges: <http://epresence.ehealthinnovation.org/epresence/1/watch/301.aspx?>: JCB, Toronto, February 11, 2009.

13. Durban, South Africa / Toronto, Canada: Recorded interview: Health research in developing countries: understanding the context. Yourprof Series: <https://www.yourprof.com/global-health-research-context/>: 27 October 2009.

2010

14. Johannesburg, South Africa: Live radio interview: Ethical and legal issues in relation to disposing with bodies of the deceased. *KayaFM*: 7-8pm, August 16, 2010.

2011

15. Durban, South Africa: Radio Interview: HIV Pre-Exposure prophylaxis. East Coast Radio Newswatch.

8 June 2011: 2.30pm.

<http://www.ecr.co.za/kagiso/content/en/east-coast-radio/east-coast-radio-podcasts?oid=1233979&sn=Detail&pid=5810&Newswatch-14h30-8Jun11>
and

11 June 2011: 11.30am

<http://www.ecr.co.za/kagiso/content/en/east-coast-radio/east-coast-radio-podcasts?oid=1241443&sn=Detail&pid=5810&Newswatch-11h30-11Jun11>

2012

16. Washington, DC, USA: Recorded interview: StoryCorp interview, Washington, DC, USA, 25 June 2012.

2014

17. Dallas, USA: Dallas Morning News interview, 12 August 2014.

<http://www.dallasnews.com/opinion/sunday-commentary/20140815-why-did-african-doctors-die-of-ebola-while-americans-got-new-treatment.ece>

18. USA: Recorded interview: National Public Radio interview, United States, 12 August 2014.

<http://www.npr.org/2014/08/12/339878597/ethics-panel-endorses-the-use-of-experimental-drugs-to-slow-ebola>.

2017

19. Amsterdam, Netherlands: Live panel interview and discussion: De Balie TV, Amsterdam, Netherlands. Data, Health and Care - Privacy over quality? Joep Lange Institute & De Balie, 5 September, 2017. <https://vimeo.com/232551202>.

2019

20. Interview: Leveraging ethics to guide HIV research priorities and policy: Q and A with Dr Jerome Singh. *Global Health Matters Newsletter*. July / August 2019; Volume 18; Number 4: 5.

<https://www.fic.nih.gov/News/GlobalHealthMatters/july-august-2019/Documents/fogarty-nih-global-health-matters-newsletter-july-august-2019.pdf>.

2020

21. Interview: Clinical trials in Africa. African Academy of Sciences. Addis Ababa. Posted: 7 July 2020. <https://www.youtube.com/watch?v=7t18CuEkqw>.

2022

22. Interview: Cape Talk. Seismic surveys. 12 January 2022.

<https://www.capetalk.co.za/podcasts/476/breakfast-with-refilwe-moloto/591070/top-scientists-call-for-end-to-outdated-seismic-surveys>.

23. Interview: Cape Pulpit 729AM. Seismic surveys. Interview: 18 January 2022. Released 20 January 2022. <https://iono.fm/e/1147340>.

2023

24. Interview: Institute for Tropical Medicine. Responsible dissemination of health and medical research. 25 January 2023. <https://www.youtube.com/watch?v=rXF-77wnx3o>.

References

On request.